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Abstract
BRINGING TIL THERAPY BEYOND MELANOMA: ADVANCING THE TREATMENT
OF ADVANCED PANCREATIC AND OVARIAN CANCERS

Donald Sakellariou-Thompson, B.S.
Advisory Professors: Chantale Bernatchez, Ph.D.
Patrick Hwu, M.D.
The success of checkpoint blockade immunotherapy (CBI) has reinvigorated the cancer
therapy field, particularly for advanced melanoma which has doubled the survival rates
compared to 20 years ago. However, there are many solid tumor types that are yet to receive
substantial benefit from this ground breaking therapy, two of which are pancreatic cancer
(PDAC) and ovarian cancer (OvCa). As such, the 5-year survival rate for PDAC and OvCa
stand at 9% and 28% respectively. Despite the lack of efficacy of CBI so far, there is still
evidence for the role of immune control in these cancers as evidenced by presence of tumorinfiltrating lymphocytes (TIL) correlating with increased survival. Since in vivo manipulation
of TIL through CBI does not seem to be sufficient to generate a strong clinical response,
approaches involving ex vivo manipulation of immune cells, such as adoptive cell therapy
(ACT) using autologous TIL, might be able to provide therapeutic benefit. The effectiveness
of TIL ACT has been demonstrated in metastatic melanoma with overall response rates
around 50%. Given this success and the anti-tumor potential of the immune infiltrate in
PDAC and OvCa, I sought to assess the feasibility of TIL ACT in these solid tumors. My
work here has demonstrated the feasibility of TIL ACT for PDAC and OvCa by showing that
they harbor an activated, anti-tumor CD8+ T-cell infiltrate that can be robustly and reliably
expanded using an improved 3-signal culture method consisting of a CD3 stimulation, an
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agonistic 4-1BB mAb, and high-dose IL-2. Additionally, these results show that TIL ACT for
PDAC and OvCa is viable regardless of primary or metastatic site and regardless of prior
chemotherapy. Furthermore, given the difficulty of treating PDAC, single-cell RNA
sequencing was used to interrogate the immune landscape to further our understanding of the
TIL heterogeneity in PDAC. Paired transcriptomic and T-cell receptor sequencing revealed
novel TIL populations with potential prognostic and therapeutic implications. A Phase II
clinical trial based on this work has been initiated at MDACC to evaluate the feasibility of
the adoptive transfer of autologous TIL in recurrent or refractory PDAC and OvCa
(NCT03610490).
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Chapter 1: Introduction
The immune system is the body’s main defense mechanism against disease and this
protection is mediated by a complex system of specialized cells and molecules. Although its
major mechanisms were only elucidated within the last 150 years, the concept of immunity
has been known, at least implicitly, since the time of Ancient Greece when it was observed
that only those people who had survived the plague could take care of the sick because they
would not contract the disease again [1]. In the 18th and 19th centuries, work by Edward
Jenner, Louis Pasteur, Robert Koch, Emil von Behring, Shibasaburo Kitasato, and Jules
Bordet provided empirical evidence for immunity [1]. However, major mechanisms of the
immune system were not revealed until observations by Elie Metchnikoff and Paul Ehrlich.
Metchnikoff discovered that there were phagocytic cells, which he termed macrophages,
which were always present in order to respond and clear pathogenic microorganisms.
Ehrlich’s research established the idea that neutralizing antibodies could be induced against a
wide array of foreign substances named antigens. Fittingly, the importance of their work was
recognized with the Nobel Prize in 1908. Since then, the importance of this work has only
grown as improved understanding of the mechanisms of the immune system has allowed for
the ability to harness its potential for treating disease. In this context, the disease that looms
large for many people is cancer in all its various forms. The Word Health Organization
estimates that the global cancer burden has risen to 18 million new cases with 9.6 million
deaths in 2018 [2]. In this introductory chapter, I intend to lay out (1) the relationship
between the immune system and cancer, (2) provide an overview of how the current
understanding of this relationship has led to the immunotherapy revolution in cancer
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treatment, with particular focus on (3) a type of immunotherapy involving the adoptive
transfer of tumor-infiltrating T cells and (4) our efforts to improve and expand its application.

1.1: The Immune System and Cancer
Metchnikoff and Ehrlich’s work laid the foundation for the two major compartments
of the immune system, innate immunity and adaptive immunity, which work in concert to
protect the body from foreign pathogens. All blood cells derive from stem cells in the bone
marrow, called pluripotent hematopoietic stem cells (HSCs), including the components of the
innate and adaptive immune system (Figure 1). The major cellular elements of both will be
discussed below in order to lay a foundation for how the actions of the immune system are
mediated.
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Figure 1. Hematopoietic stem cell differentiation.
Bone marrow-derived hematopoietic stem cells give rise to the common myeloid and
lymphoid progenitor cell, which themselves differentiate into the major cellular components
of the immune system.

1.1.1 Innate Immunity
Innate immunity is the first line of defense, and it is responsible for non-specific but
immediate responses that can feed into adaptive immunity. This consists of several
components, but the main and largest one that I will highlight is the myeloid cellular
component. Myeloid cells arise from the common myeloid progenitor cell (CMP), which
itself originates from bone marrow HSCs [1]. Along with the macrophages first described by
Metchnikoff, the myeloid component is comprised of other phagocytic cells like dendritic
cells and several kinds of granulocytes. While having the similar property of engulfing
pathogens, they also have other important functions that are briefly described below:
Macrophages. One of the blood cell types that arises from CMPs following
differentiation from HSCs are monocytes, which circulate in the blood before entering
various tissues and maturing into macrophages. These cells are the main phagocytic cell (i.e.
they engulf pathogens) in the body and are found in most tissues trawling for foreign
microorganisms to clear. Macrophages also participate in initiating larger immune responses
by producing inflammatory mediators and by functioning as antigen presenting cells (APCs).
APCs present antigens to the effector cells of the immune system using a class of surface
receptor known as the major histocompatibility complex (MHC; also known as Human
Leukocyte Antigen [HLA]). Antigen presentation is a highly integral part of bridging the
innate and adaptive immune responses which will be discussed further in section 1.1.5.
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Dendritic cells. Also deriving from the CMP, immature dendritic cells (DCs) exit
the bone marrow into circulation and enter various tissues, such as the skin or gastrointestinal
tract, constantly checking for pathogens. While DCs have phagocytic capacity as well, they
also constantly sample material from the extracellular space, process it internally, and present
small pieces of this material, known as antigens, on their surface. If a DC becomes activated
during this process, it will migrate from the tissue to the nearest lymph node to interface with
adaptive immune cells. This process allows them to perform their main and most important
function as an APC.
Granulocytes. The third major cell population that arises from the CMP is the
granulocytes, which consists of neutrophils, eosinophils, basophils, and mast cells. They are
named granulocytes due to the many granules of degradative enzymes they secrete or use to
breakdown phagocytosed pathogens. Neutrophils are the most abundant granulocyte (60-70%
of white blood cells) and are a major responder to infection. Eosinophils, basophils, and mast
cells are less abundant and mainly respond to parasites as well as allergic reactions. All
provide a very fast response (minutes) and are short-lived.
The components of the innate immune system are often called sensor cells because
they express receptors that allow them to detect various inflammatory mediators. These
innate receptors are called pattern recognition receptors (PRRs) because the recognize
molecules common to various pathogens or indicators of cell stress. Unlike the lymphocyte
receptors that will be described in the following section, these innate receptors do not have a
highly variable repertoire of specificities.
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1.1.2 In between innate and adaptive immunity
Two other cell types worth mentioning with regard to innate and adaptive immunity
are the natural killer (NK) cell and the gamma-delta (γδ) T cell. While these cells derive
from the CLP and are considered lymphocytes, they do not possess the hypervariable antigen
receptors that define B cells and T cells [1]. These cells can be thought of as occupying a
transitional space between innate and adaptive immunity due to sharing characteristics of
both systems. They are briefly described below:
NK cells. Although it is a lymphoid cell, NK cells also display several characteristics
of innate immune cells. They lack hypervariable antigen-specific receptors and instead
express several types of innate receptors that allow them to quickly respond to cellular stress
or infection. They are also able to recognize and destroy antibody-coated pathogens via Fc
receptors which recognize the “base” of antibodies (Figure 2A). As such, NK cells bypass the
need for antigen recognition in the context of MHC, and in fact will also target cells that do
not express MHC. Additionally, recent findings suggest that they have most features of
adaptive immunity except for the antigen-specific receptors. As such it has been proposed
that they occupy the evolutionary space between innate and adaptive immunity [3].
γδ T cell. This type of T cell is defined by expression of distinctive, invariant TCRs
that is composed of a TCRγ and TCRδ chain, hence the name. While γδ T cells have many
phenotypic and functional similarities to αβ T cells, the difference in TCR allows them
recognize antigens directly on the surface of target cells, outside of the context of MHC.
They also have a much more limited repertoire of antigen specificity and may even function
similarly to an innate immune cell in terms of pattern recognition. The complete role of γδ T
cells and their antigen targets are still being elucidated.
5

1.1.3 Adaptive immunity
Ehrlich’s work, among others, hinted at the existence and function of adaptive
immunity. This system is composed of highly specialized cells, called lymphocytes, which
arise from the common lymphoid progenitor (CLP) in the bone marrow [1]. Each of these
lymphocytes express antigen receptors with a specificity unique to each cell (Figure 2).
When these cells divide, the unique antigen receptor will be passed on to the daughter cells
which are often referred to as clones due to sharing the unique receptor. This diverse
repertoire of antigen specificity is what allows the immune system to ultimately respond to
almost any challenge. The hypervariability of these antigen receptors is accomplished
through random genetic recombination of several hundred gene segments to generate a
seemingly infinite range of specificities. The two main lymphocyte cell types are described
below:

6

Figure 2. Structure and function of B- and T-cell antigen receptors.
(A) The B-cell receptor is a Y-shaped protein consisting of two chains. At the forked-end of
the Y is the variable region where the receptor binds its cognate antigen. After a B cell is
activated, it beings to secrete its receptor in the form antibodies. These bind to their targets in
order to neutralize or mark them for clearance. (B) The T-cell receptor consists of two
chains, the most common pairing being the alpha- and beta-chains. The T-cell becomes
activated after recognizing its antigen in the context of MHCI, which is generally on the
surface of a dendritic cell. After activation, the T cell will traffic through the body until it
again recognizes its target on the surface of a tumor cell and destroy the target cell.
B lymphocytes. Also known as B cells, these lymphocytes are white blood cells that
differentiate from the CLP in the bone marrow and then circulate in the peripheral blood as
well as reside in lymph nodes. As mentioned, each express a unique antigen receptor (the B
cell receptor or BCR) that is essentially a membrane-bound antibody. Upon recognition of an
antigen via their BCR, B cells become activated and secrete Y-shaped proteins called
antibodies with the same specificity as the BCR (Figure 2A). These antibodies can bind to
7

targets to either neutralize them directly or mark them for clearance by innate immune cells
like macrophages. Therefore, B cells are the cellular mediators of the humoral immune
response that Ehrlich described. Additionally, B cells can also act as APCs for T
lymphocytes to direct their response.
T lymphocytes. Also known as T cells, this class of lymphocyte is the main effector
cell of the adaptive immune system. T cells express their own antigen-specific receptor
known as the T-cell receptor (TCR) that is composed of a TCRα chain and TCRβ chain
(Figure 2B). Thus these T cells are often called αβ T cells. Upon recognition of a unique
antigen through their TCR, T cells become activated and differentiate into either cytotoxic,
helper, or regulatory T cells. Respectively, these cells can clear cells that express the antigen
target (CD8+ cytotoxic T cells), help support the immune response (CD4+ helper T cells), or
even suppress the response of other immune cells (CD4+ regulatory T cells). Importantly, T
cells can only recognize their antigen when it presented in the context MHC Class I
molecules, which are present on the surface of all cells in the body (Figure 2B). T cells do
not secrete their antigen receptor like B cells. Instead, they engage the target cell directly
through the TCR:MHCI interface.
The adaptive immunity arm of the immune system is an amazing and powerful
weapon for not only its vast array of antigen specificity, but also its capacity for
immunological memory. The name adaptive refers to this extremely important function.
After being exposed to a pathogen, the body “adapts” by maintaining a small population of
lymphocytes that were specific for the pathogen so that it can more readily respond in the
event that pathogen is encountered again. This was the principle behind the success of early
vaccine studies done by Jenner and others.
8

1.1.4 T-cell differentiation and plasticity
T-cell development, occurs primarily in the thymus, a specialized lymphoid organ
located behind the sternum. After development, T cells enter the blood as so-called naïve T
cells (TN) and migrate to peripheral lymphoid organs, such as lymph nodes, where they can
be activated by antigens. Following activation, both CD8+ and CD4+ T cells can differentiate
into several classes of T cells that are discernable by expression of certain surface markers
and different, specialized functions [4]. Beyond TN, the generally accepted classes of T cells
are central memory (TCM), effector memory (TEM), and terminally-differentiated effector
memory (TEMRA) (Figure 3). In addition to these, recent data has suggested the existence of
T-cell subset between TN and TCM called T stem-cell memory (TSCM) with putative stem-cell
like attributes like self-renewal and multipotency [5]. While the exact model for T-cell
differentiation is still debated, the general consensus is that these main T-cell states fall along
a spectrum of progressive differentiation where TN leads to TSCM, then TCM, then TEM, and
then finally ending with TEMRA [5] (Figure 3A). As T cells progress along this continuum,
they become more differentiated and more short-lived. For example, TCM can persist long
term in the body until they encounter their antigen, upon which a subset can differentiate into
TEMRA and die off shortly after executing their effector function [4].
The contribution of CD4+ effector T cells is key to an efficient CD8+ T-cell immune
response, as well as programming of optimal memory T-cell subset formation. As such, they
are often referred to as CD4+ helper T cells (TH). Within the CD4+ TEM subset, there are
several well-defined TH subsets: TH1, TH2, TH17, and follicular helper T cells (TFH) (Figure
3B) [1, 6]. The differentiation of naïve CD4+ T cells into each of these subsets is mainly
governed by specific cytokines (immune-stimulating proteins secreted by immune cells) in
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the local environment after activation. TH1 are mainly involved in augmenting the CD8+ Tcell immune response against intracellular pathogens, and have been known to possess
cytotoxic effector function as well [7, 8]. TH2 coordinate the immune response against
parasites while TH17 participate in clearance of extracellular bacteria and fungi. TFH a unique
subset of helper T-cell that helps recruit B cells to peripheral lymphoid tissues (e.g. lymph
nodes) as well as help regulate their response. In addition to these CD4+ effector T cell
subsets, there is another important subset called regulatory T cells (Tregs) that modulate and
suppress the response of CD8+ and CD4+ effector T cells [9]. While Tregs can develop
naturally in the thymus, they can also be induced in the periphery (iTreg) by exposure to
certain cytokines, similar to the other CD4 subsets.
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Figure 3. Differentiation and plasticity of T cells.
(A) After a naïve T-cell gets activated by an antigen presenting cell like a dendritic cell, it
starts to proliferate and follow a progressive differentiation trajectory involving the different
T-cell states. This trajectory can pause at the TSCM or TCM stage, but it eventually ends with
the short-lived terminally differentiated effector cell (TEMRA). (B) CD4+ Helper T cells can
differentiate (solid arrows) into several different classes initially depending on the signals
received but also maintain the flexibility to repolarize (dashed arrows) to another state if the
signals in the local environment change.
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It is important to note that TEM are not necessarily locked-in to the effector lineage
they initially occupy. There is flexibility in the programming of their phenotype, which is a
concept known as T-cell plasticity [4, 10]. Depending on changes in the T cells’ local
environment, TEM can transition to a different phenotypic state. Evidence has been presented
for this regarding the ability of the various CD4+ TH subsets to be repolarized to a different
state based on the cytokine signals they receive [10]. For example, it is well-known that
TH17 cells can be reprogrammed into TH1 cells with the right cytokine signals [11]. The idea
of T-cell states being affected by their environment has taken on particular importance in
regard to understanding CD8+ TEM function in the context of tumors. The data strongly
suggest that functional CD8+ TEM that have infiltrated tumors follow a trajectory that
eventually ends at a state of dysfunction that is driven by cues from the tumor and its
microenvironment [12].
The phenotypic and functional changes that mark T-cell differentiation and state
changes are mediated by a cascade of alterations in gene expression. These transcriptional
changes are governed by expression of key transcription factors that act as master regulators
of each T cell state, either independently or in a graded manner [5-7]. The expression of
transcription factors associated with TN cells (e.g. TCF7, LEF1, KLF2) is progressively lost
as cells transition through the different differentiation states (i.e. TSCM to TCM and TEM). In
their place, transcription factors associated with effector cell function are upregulated (e.g.
EOMES, TBET, BLIMP-1). In fact, for CD8+ T-cell differentiation, the interplay between
EOMES and TBET are key to determining the properties of T cell populations within the
TEM subset [13]. Similarly, the different CD4+ TEM helper T-cell subsets are controlled by
well-defined transcription factors. The TH1, TH2, TH17, TFH, and iTreg phenotypes are
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regulated by expression of TBET, GATA3, RORγC, BCL-6, and FOXP3 respectively [6, 7].
Expression of these transcription factors changes accordingly during conversion of one TH
subset to another. Ultimately, understanding mediators of these different T-cell states, as
well as the relationship between the different states, is key to harnessing the immune
system’s potential.

1.1.5 Initiation of an adaptive immune response
With the major players of the immune system laid out, it will be important to
delineate the general cascade of events that comprises an immune response as they will be
relevant later. Furthermore, while all the cells discussed in the previous section play an
important role in an immune response, the role of cytotoxic CD8+ T cells is germane to the
core of this dissertation, and so the events discussed in this section will focus specifically on
their function (Figure 4).
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Figure 4. Initiation of an adaptive immune response against tumor.
In step (1) of the cycle, cancer antigens are released due to oncogenesis. These are eventually
taken up by dendritic cells in step (2). Dendritic cells traffic to the lymph node in step (3) in
order to present the antigen to T cells, which activates them. Upon activation, T cells leave
the lymph node and traffic to the tumor site (4) and infiltrate it (5). Up recognition of its
cognate antigen (6) that is bound to MHCI and expressed on the surface of the tumor, the T
cell kills the target cell (7).

In this context, an adaptive immune response involving T cells is initiated when they
encounter antigens for which their TCR is specific [1]. This encounter occurs in the context
of DCs displaying the antigen on their surface while bound to an MHC Class I molecule
(MHCI). DCs accomplish this through a process called cross-presentation. As mentioned in
section 1.1.2, DCs regularly uptake pathogens or molecular components from the
environment which are then degraded intracellularly. The proteins are broken down into
small fragments called peptides, which must be 9-12 amino acids in length for CD8+ T cells
to recognize. These peptides are then loaded onto MHCI receptors inside intracellular
vesicles in DCs. The peptide:MHCI complexes then traffic to the surface of the DC where
they are displayed for T cells to interact with. The antigens that CD8+ T cells recognize via
DC presentation are the peptides that have gone through this antigen processing pathway.
DCs usually encounter antigens at the site of pathogenic inflammation (e.g.
infection). While there, inflammatory signals in the milieu also activate the DCs which cause
them to express co-stimulatory surface molecules and secrete stimulatory cytokines. After
activation, DCs will migrate to nearby lymph nodes, which are specialized immune organs
that contain high densities of innate and adaptive immune cells in close proximity, in order to
present it to a T cell with a TCR specific for that antigen. Concomitant co-stimulation of a T
cell after activation of its TCR is also required in order to sustain the T cell activation and
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proliferation. These co-stimulatory signals are provided by the activated DC expressing the
aforementioned cytokines and cell-surface molecules. After activation, T cells will clonally
expand, leave the lymph node as effector cells and travel to the tissue site where they will act
to clear the threat. CD8+ T cells are able to recognize their target cells because they will also
be displaying the antigen, bound to MHCI, on their surface. This migration is helped by
inflammatory and chemotactic signals produced at the site of inflammation and that diffuse
into gradients that direct immune cells. The antigen-specific population of T cells will
contract once the target is cleared, leaving behind a small percentage of these cells that have
differentiated into long-lived memory cells. These memory cells persist, either in the
peripheral blood or at the tissue site, and serve as a line of rapid response in the event the
antigen is encountered again.
Following this general set of events, T cells are involved in the immunological
clearance of many foreign pathogens that replicate inside the body’s cells like bacteria,
viruses, and some parasites. After inflammatory signals produced by the pathogenic invasion
draw T cells to the area, the T cells are able to recognize the infected cells because they
display antigens derived from the pathogens on their surface in association with MHCI.
These antigens are recognized as non-self and trigger the T cells’ cytotoxic function. The
recognition of non-self by T cells goes beyond pathogens or microorganisms to include a
multifaceted disease that is derived from normal cells in the body: Cancer. Indeed, it has
been well established that abnormally expressed proteins in cancer are a major source of
immunogenic antigens [14, 15]. With cancer being major health problem worldwide and the
second leading cause of death in the United States, cancer therapy has also been a major
focus of research for decades [16]. In recent years, particularly attention has been given to
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understanding the immune system’s role in controlling cancer and developing methods to
harness its potential.

1.1.6 The immune surveillance of cancer
Cancer is characterized by the accumulation of several genetic mutations that confer
aberrant regulation of cell proliferation and developmental pathways, leading to unchecked
tumor growth and spread. The steps needed for malignant transformation of normal cells to
cancer cells were famously laid out by Hanahan and Weinberg in their “Hallmarks of
Cancer” report [17]. These were as follows:
1. Evasion of cell death (apoptosis)
2. Self-sufficiency in growth signals
3. Insensitivity to anti-growth signals
4. Aberrant vascular growth (angiogenesis)
5. Unlimited replicative potential
6. Tissue invasion and metastasis
In addition to the original six hallmarks identified, one of the new hallmarks posited by a
follow up to this report in 2011 is the ability for cancer to evade the immune system [18].
While not a new idea, the inclusion of this hallmark highlights the relatively recent
widespread acceptance of the role of the immune system in cancer control.
In 1909, it was again Paul Ehrlich who is credited with first proposal for the role of
the immune system in controlling cancer, even though he was unable to confirm this
experimentally [19]. Perhaps the first experimental report of stimulating an immune response
against cancer was reported by Ludwik Gros in 1943. Gros showed that intradermal
immunization of mice with a sarcoma tumor line was able to induce protection against
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rechallenge in some mice [20]. In the late 1950’s, the theory of immune surveillance of
cancer was proposed separately by Frank MacFarlane Burnet and Lewis Thomas [21, 22].
They hypothesized that the immune system could recognize cancer cell neoantigens and
respond to eliminate the nascent tumors. However, it was not until the 1990’s that the tools
were available to truly evaluate the role of immunity in cancer. Using mice that lacked fully
functional immune systems, Robert Schreiber and colleagues showed that these mice were
more susceptible to tumor formation and growth [23-25]. In the years since, this finding has
been recapitulated by several others [26].
As alluded to, mutations acquired by cancer cells result in the expression of antigens
that are not natively expressed and thus elicit an immune reaction. This then raises the
question: if the immune system is constantly surveilling the body for signs of non-self, such
as those displayed by cancer, then how does a tumor manage to form? This question led to a
revision of the cancer surveillance hypothesis that is now referred to as cancer
immunoediting and encompasses three phases of tumor growth: (1) elimination, (2)
equilibrium, and (3) escape [1].

1. The elimination phase is simply the previous working theory of immunosurveillance
where the immune system recognizes and eliminates cancer cells.
2. The equilibrium phase involves tumor dormancy where residual tumor is kept in
check by the immune system. It is likely during this phase that the immune system
effectively selects populations of tumors cells that have acquired immune evasion
mechanisms.
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3. The final escape phase consists of these resistant tumor cells breaking through the
control. Mechanisms for immune evasion can be due to either changes in the tumor
cells or the tumor microenvironment (TME).

The phases of cancer immunoediting illustrate the potential of the immune system to not
only affect tumor control but shape its immunogenicity. Understanding this has launched the
immunotherapy revolution over the past two decades by helping to inform development of
immune-oncology strategies that can harness the power of the immune system to prevent and
treat cancer.

1.2: Cancer Immunotherapy
With the role of the immune system in tumor control having been well established,
there has been a large effort to develop immunotherapies that can exploit and augment this
control. Targeting of CD8+ T cells has been of particular focus due their role as main
cytotoxic effector cells of the adaptive immune system and because the presence of CD8+
tumor-infiltrating lymphocytes (TIL) has been correlated with better prognosis in several
cancer types [27]. However, factors either intrinsic to the tumor or its local environment
often develop that lead to dysfunctional tumor-immune cell interactions [18]. Tumor escape
can be due to a single factor such as impaired antigen recognition or due to a more
complicated web of immunosuppressive factors in the TME. An immunosuppressive TME
can be mediated by recruitment of regulatory immune cells, lack of co-stimulatory signals
due to expression of inhibitory receptors, or a milieu inhospitable to immune cell function
[26]. As a result, immunotherapy development has been focused on overcoming these
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barriers and several important modalities tested in clinical trials are summarized in the
following subsections (Figure 5).

Figure 5. Immunotherapies that have been developed to boost cancer immunity.
There are several immunotherapeutic options that can affect the T-cell anti-tumor response
and which mediate their effect at various points throughout the cycle. Immunotherapies
mentioned in this section are highlighted in the figure.
1.2.1 Cytokine Therapy
Perhaps the first example of modern immunotherapy was the use of recombinant
cytokines, which are small, often immunostimulatory molecules that are secreted by all
immune cells. In particular, the identification of the T cell growth factor interleukin-2 (IL-2)
in 1976 was a major breakthrough for the field of immunotherapy [28]. In 1984, Steven
Rosenberg demonstrated its therapeutic potential after treatment of a metastatic melanoma
patient with systemically administered IL-2 resulted in a complete response (CR) that has
continued for 30 years [29]. Not only was this the first example of an effective
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immunotherapy in humans but it also hinted at the possibility of durable responses. Several
follow up studies resulted in high-dose (HD) IL-2 being approved by the Food and Drug
Administration (FDA) for treatment of metastatic renal cancer in 1992 (20% overall response
rate [ORR]) and metastatic melanoma in 1998 (16% ORR) [29].
Interferon-α (IFN-α) was another notable entry in the immunotherapy treatment of
metastatic melanoma. IFN-α is known to induced expression of MHCI on tumor cells as well
as to activate immune cells [1]. It was approved in 1995 by the FDA after clinical trials
indicated IFN-α provided a significant benefit in relapse-free survival (1 year vs. 1.7 years)
of cutaneous melanoma in the adjuvant setting [30]. Since then, a modified version with an
improved half-life was also approved in 2011 for resected melanoma [31]. However, using
IFN-α is highly toxic is no longer used as the standard of care due to the advent of a class of
immunotherapy discussed in the next section.
While IL-2 and IFN-α are the only two approved cytokine immunotherapies for
cancer, others have been investigated such as IL-7, IL-15, and IL-21. IL-7 and IL-15 help
promote T cell homeostasis and expansion of memory T cells while IL-21 promotes CD8+ T
cell activation as well as proliferation [32]. Early clinical trials for agonists of all three show
signs of activity [33-35]. Additionally, a pegylated version of IL-2 that showed improved
safety and pharmacodynamics in patients and is being studied in combination with other
immunotherapies [36].

1.2.2 Immune Checkpoint Inhibitors
Immune checkpoint inhibitor therapy, also known as checkpoint blockade
immunotherapy (CBI), is a revolutionary class of immune-oncology drugs. When T cells
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become activated, they not only upregulate several costimulatory receptors to help sustain
and propagate their response, but they also begin to express inhibitory receptors to
counterbalance the activation [37]. These inhibitory receptors are referred to as immune
checkpoints and their natural function is to help moderate the strength and duration of a T
cells’ activation to limit indiscriminate cytotoxicity. Tumors are able to take advantage of
these immune checkpoints by recruiting cells to the TME that express the ligands for these
inhibitory receptors or by upregulating these ligands themselves. Key immune checkpoint
molecules that are targets for therapeutic inhibition are summarized below.
CTLA-4. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was the first
immune checkpoint receptors targeted in the treatment of cancer patients, following a body
of work supporting its role in negative regulation of T cells. CTLA-4 is known to be
expressed exclusively on activated effector T cells and can mediate immune suppression
[37]. It was first discovered in 1987, but it wasn’t until 1995 that its function as a negative
regulator of T cell activation was discovered [38-40]. Shortly thereafter, its mechanism of
action was first described by Jim Allison and colleagues when they showed that it works in
direct opposition to CD28 costimulation, a major positive signal for T cells after TCR
activation, by preferentially binding to the same ligands [41]. Allison and colleagues
followed up with a pivotal experiment that showed an enhancement of anti-tumor immunity
via CTLA-4 blockade with an antagonistic antibody [42]. This work led to the development
and clinical testing of Ipilimumab, a fully humanized anti-CTLA4 antibody. After a key
phase III trial showed Ipilimumab to be the first drug to demonstrate survival benefit in
advanced melanoma patients, the FDA approved it for this indication in 2011 [43]. For his
work on developing CBI, Jim Allison shared a Nobel Prize in 2018.
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PD-1. Programmed cell death protein 1 (PD-1) is another key checkpoint molecule
and it was the second one targeted clinically. PD-1 is known to be upregulated on activated
effector T cells as a result of chronic antigen stimulation, particularly on T cells that have
infiltrated the tumor tissue [44]. Tasuku Honjo and colleagues first identified PD-1 in 1992
and demonstrated its immune regulatory function a few years later [45, 46]. Further evidence
by several other groups demonstrated that PD-L1, the ligand for PD-1, could be upregulated
on tumor cells and mediate immune resistance [47, 48]. Evidence of upregulation of the PD1/PD-L1 axis on T cells and tumor cells prompted development and testing of several antiPD1 and anti-PDL1 antibodies. Two anti-PD1 antibodies, Pembrolizumab and Nivolumab,
were approved by the FDA in 2014 for the treatment of melanoma after they showed durable
responses in patients [49, 50]. Since then anti-PD1/PD-L1 drugs have been approved for a
variety of other cancers, including the use of Pembrolizumab for cancers with specific
genetic mutations (Microsatellite unstable a.k.a. MSI high) regardless of the origin. Tasuku
Honjo shared the Nobel Prize with Jim Allison in recognition for his contribution to the area
of CBI.
Several other immune checkpoint molecules have emerged a potential targets, such as
TIM3, LAG3, TIGIT, VISTA. All of these receptors, except for VISTA which is expressed
mainly on myeloid cells, are predominantly expressed on antigen-activated T cells and thus
are prime axes for mediating immune suppression at the tumor site. As such, there are several
clinical studies exploring their inhibition as either monotherapy or in combination with
already approved checkpoint inhibitors [32, 37]. The successes seen with checkpoint
inhibitors have made them the frontline option for several indications and have energized the
immunotherapy field.
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1.2.3 Costimulatory activation of T cells
On the opposite side of the coin from reinvigorating T cells through checkpoint
inhibition is doing it by activation through costimulatory signaling pathways. The importance
of CD28 as a costimulatory pathway to augment TCR signaling after T cell activation has
been known since the early 1990s [51]. Other T cell costimulators have been identified as
well that can potentially be targeted to augment antitumor immunity. Several of the key
costimulatory receptor targets on T cells are discussed below.
4-1BB. 4-1BB/CD137/TNFRSF9 belongs to the tumor necrosis factor receptor
superfamily (TNFRSF), which consists of several receptors that promote T cell survival and
proliferation. This receptor can be expressed on several types of immune cells such as T
cells, B cells, NK Cells, and DCs [52]. Ligation of 4-1BB with its ligand, 4-1BBL, provides
pro-survival, activation, proliferation, and effector function signals through the NFκB and
MAPK kinase pathways [53, 54]. With regard to T cells, 4-1BB typically becomes
upregulated on recently antigen-activated CD8+ T cells and reaches peak expression around
24 hrs [55]. 4-1BB agonists demonstrated improvement of anti-tumor activity in mouse
models, however use of one 4-1BB agonist in the clinic resulted in severe liver toxicities [52,
56, 57]. It was found that this hepatotoxicity was mediated by a4-1BB activating IL-27producing liver myeloid cells [58]. Anti-41BB in combination with other therapeutics is
being explored in several trials [59].
OX40. OX40/CD134/TNFRSF4 is another member of the TNFRSF family that is
expressed at much higher levels on CD4+ T cells than CD8+ T cells after peptide stimulation
in humans [54]. OX40 functions similarly on CD4+ T cells as 4-1BB does for CD8+ T cells in
that it also provides survival and proliferation signals through the same pathways [54]. Much
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work on agonistic OX40 antibodies has been done in mouse models where both CD8+ and
CD4+ T cells can express OX40 [60]. Targeting OX40 has induced T-cell mediated tumor
regression in mouse models as well as promote generation of effector and memory T cells
[60]. There is also evidence to suggest that OX40 costimulation can abrogate CD4+ Treg
activity [61, 62]. An early clinical trial showed that treatment with an anti-OX40 was able to
induce tumor regression in 40% of patients [63]. Patients also showed increased CD4+ as
well as CD8+ T cells in the blood, which was accompanied by increased in vitro anti-tumor
response [63]. Anti-OX40 in combination with other therapeutics is being explored in several
trials [59].
ICOS. Inducible T-cell costimulatory (ICOS)/CD278 is a member of the same family
of costimulatory receptors as CD28 and is expressed mainly on activated CD4+ T cells. Data
suggests that ICOS stimulation may have indirect effects on anti-tumor response as it did not
induce a strong response by itself in mouse models [59]. However, it does appear to provide
benefit in the context of CBI. ICOS was found to be upregulated on CD4+ T cells after antiCTLA4 treatment, and subsequent ICOS simulation increased the cytotoxic T cell response
[64]. Upregulation of ICOS after CTLA-4 blockade was also found in patients, suggesting
stimulation of this pathway may enhance CBI efficacy in future trials [65]. Agonistic ICOS
antibodies have only recently become available for clinical testing.
GITR. Glucocorticoid-induced TNFR-related protein (GITR)/CD357/TNFRSF18 is a
third member of the TNFR family. It is found on low levels of CD4 and CD8 T cells and is
upregulated after TCR activation [66]. However, it is constitutively expressed a high levels
on regulatory CD4+ T cells [67]. Stimulation of GITR on CD8+ T cells can enhance antigenspecific CD8+ T-cell response, which is probably mediated in part by inducing resistance to
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Treg suppression [68, 69]. Data from mouse models showed that GITR agonism either alone
or in combination with anti-PD1 or anti-CTLA4 could induce tumor regression that was T
cell dependent [70, 71]. A recent clinical trial in patients with advanced, refractory cancers
reported that GITR agonism combined with PD-1 blockade resulted in reduced Tregs levels
systemically and in the tumor as well as enhanced CD8+ T cell activity [72].

1.2.4 Cancer Vaccines
Cancer vaccines take advantage of the first step in initiating an immune response,
which is antigen presentation by DCs to prime T cell responses The goal of vaccination is to
use DCs loaded with either tumor cells or tumor-associated antigens (TAA), to augment the
immune response against cancer. The use of an adjuvant is required to help stimulate the
immune system to respond to the tumor antigens, as is the case with traditional vaccines
against microbial agents.
There are currently two FDA approved cancer vaccines that use tumor antigens. The
first is Sipuleucel-T, which is an autologous DC vaccine used to treat castrate-resistant
prostate cancer [73]. The vaccine works by incubating the patients’ DCs with a nearly
universally expressed prostate cancer TAA as well as the DC stimulating cytokine
granulocyte-macrophage colony-stimulating factor (GM-CSF), and then reinfusing them into
the patients. This treatment only improved survival by 4 months [73]. The second is T-VEC,
which takes advantage of stimulating the immune system with tumor antigens in round-about
way. T-VEC uses an oncolytic herpes virus that is modified to be less virulent as well as to
express GM-CSF. The vaccine is designed to elicit a systemic anti-tumor response by
infecting cancer cells and causing them to burst, spreading antigens. It was approved in 2015
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for late stage melanoma and produced a 26.4% ORR vs. 5.7% ORR for patients who only
received subcutaneous GM-CSF [74].
Beyond these, there are several cancer vaccines in development that use either
modified tumor cells and/or TAAs. In particular, many TAAs have now been identified and
cancer vaccines could be a prime way to take advantage of directing the immune system
against targets specific to tumor cells. A phase III trial in stage III and IV melanoma using a
gp100 peptide vaccine plus IL-2 showed only a small improvement in progression free
survival compared to IL-2 alone. (2.2 months vs. 1.2 months) [75]. A TAA-based vaccine in
Her2+ breast cancer, where patients were immunized with a Her2 peptide plus GM-CSF,
showed modest clinical activity in an early phase clinical trial (89.7% vs. 80.2% disease-free
survival) [76]. Another clinical trial by Elizabeth Jaffee and colleagues utilized GM-CSF
secreting allogeneic pancreatic tumor cells in combination with live-attenuated Lysteria
expressing mesothelin, which is a pancreatic cancer TAA [77]. Unfortunately, the
combination did not improve survival over chemotherapy.
In addition to targeting shared TAAs, there are also efforts to treat patients with so
called personalized cancer vaccines. These studies identify neoantigens (i.e. new antigens
expressed only by cancer cells typically due to a mutation) that are not only highly specific to
the cancer but also to each individual patient, too. Several studies were done in melanoma
patients, demonstrating induction of neoantigen specific T cells as well as clinical benefit
[78-80]. Furthermore, a more recent neoantigen vaccine trial showed similar T cell responses
in glioblastoma [81]. Among others, there have also been efforts at MD Anderson Cancer
Center to treat metastatic colorectal cancer and pancreatic cancer patients with personalized
peptide cancer vaccines. Indeed, within the past few years, several other trials involving
26

peptide-based anticancer vaccines were terminated early due to lack of efficacy or lack of
scientific rationale to continue [82]. While vaccination can induce antigen-specific T cells,
evidence suggests that combination with other immunomodulatory agents (like the ones
mentioned in the previous subsections) will be needed to induce tumor clearance. As such,
there are several current studies that are addressing this need by combining cancer vaccines
with blockade of PD-1, CTLA4, TIM3, LAG3 or costimulation of 4-1BB, OX40, GITR,
CD27 [83, 84].

1.3: Cellular Immunotherapy for Cancer
The presence of T cells in the tumor, particularly CD8+ T cells, has been correlated
with improved survival in a myriad of cancer types which is suggestive of their anti-tumor
potential [85-92]. From current general immunology knowledge of T cell function, it is likely
that at least some of the T cells in the tumor have migrated and arrested there in response to
the tumor [1, 93]. As already stated, the idea that tumors can persist despite the presence
tumor-infiltrating lymphocytes (TIL) led to the identification of several mechanism of tumor
immune evasion which have been discussed. Futhermore, the identification of IL-2 as a
soluble T-cell growth factor allowed ex vivo propagation of T cells in order to study their
function. Taken all together, this knowledge provided the rationale for exploring cellular
immunotherapies with adoptively transferred T cells. In general, adoptive cell therapy (ACT)
uses the idea that by removing TIL from a restrictive and immunosuppressive environment,
they can be reinvigorated and expanded to prognostically favorable numbers. Transfer of
these cells back to the patient as a large boost of anti-tumor immunity can result in
eradication of established tumors and long-term progression-free survival [94, 95]. T-cell
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therapy was pioneered by Steven Rosenberg using TIL based ACT for the treatment of
melanoma in the 1980s. Since then, attempts to build on the success of TIL ACT in
melanoma have included genetically engineering lymphocytes (including NK cells) to
express chimeric-antigen receptors (CAR-T), antigen-specific TCRs, or receptors to improve
their functionality at the tumor site. Since ACT is central to the work in this dissertation,
these strategies will be discussed at length in this section (Figure 6).

Figure 6. The three main forms of adoptive cell therapy.
Adoptive cell therapy is a form of immunotherapy that augments the patient’s anti-tumor
response by transferring large numbers of ex vivo expanded T cells. The first (1) approach is
engineering T cells, typically taken from the blood, using viral vectors to express either a
chimeric antigen receptor (CAR) or antigen-specific T-cell receptor. The second (2) method
relies on the isolation and expansion of low-frequency antigen-reactive T cells from the
blood. The third (3) therapy grows tumor-infiltrating lymphocytes ex vivo from patients’
biopsies or resected tumors.
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1.3.1 Adoptive cell therapy with tumor-infiltrating lymphocytes
The basic principle of TIL ACT involves the patient’s tumor being resected, cut into
small fragments, and cultured with IL-2 to stimulate expansive TIL growth ex vivo [96].
Once the TIL reach sufficient number, they undergo a second large expansion phase to be
able to reinfuse billions of cells into the patient to effect tumor clearance [96]. The first
example of this was demonstrated by Rosenberg and colleagues in a murine model of
lymphoma, and its effect was further enhanced with systemic IL-2 administration following
TIL infusion [97, 98]. Observation that human anti-tumor TIL could be consistently isolated
from melanoma led to the first demonstration that ACT with autologous TIL could mediate
tumor regression in melanoma patients [99-101]. Despite these early promising results, the
duration of responses (DOR) was often short-lived (2-13 months) and infused TIL rarely
persisted for more than a few days in the patient [102].
As such, Rosenberg and colleagues at the NCI worked to improve the early TIL
generation and administration process. A major development was the observation that
lymphodepletion of patients prior to adoptive TIL transfer improved response as well as
engraftment of the transferred cells. Mechanistically, the superior TIL persistence afforded
by lymphodepletion is believed to be mediated by the removal of endogenous homeostatic
cytokine sinks by the lymphodepleting regimen [103, 104]. Furthermore, a “young TIL”
culture protocol was established that reduced culture time, and increased patient eligibility
was achieved by making the assumption that all TIL cultures contain anti-tumor activity and
removing the TIL reactivity testing step, thus making TIL ACT more accessible. While the
young TIL method did decrease the time of culture and had attributes associated with better
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persistence, it resulted in response rates below what was reported for the traditional method
(35% vs. 49% ORR) [94, 105, 106].
With the success of TIL ACT in melanoma established at by Rosenberg and
colleagues, other medical centers have sponsored clinical TIL ACT trials for melanoma and
there have been 13 studies to date that followed the general protocol laid out by the National
Cancer Institute [107]. Since most (8/13) trials use HD IL-2 after TIL infusion, which is the
model followed at MD Anderson Cancer Center in particular, only the results of these trials
will be discussed as they are the most relevant. A meta-analysis of these trials found that the
ORR at the different centers were consistent with each other, indicating the reproducibility of
TIL ACT [107]. The overall ORR was 43%, which included 15% CR and 28% partial
responses (PR). From the available data, the overall median DOR was not reached for CRs
after 48 months and 11.5 months for PRs. Furthermore, a TIL dose consisting of ≥50x109
cells and a more CD8+ TIL rich product were both correlated with better response [107-109].
Given the potential, there have also been attempts to push TIL ACT beyond
melanoma, particularly for cancer types in need of improved therapies and that have not yet
responded well to CBI. Several recent preclinical and clinical studies have been published in
ovarian cancer, various gastrointestinal (GI) epithelial cancers, colorectal cancer, HPV+
cervical cancer, breast cancer, pancreatic cancer, and non-small cell lung cancer [110-120].
Efforts to further improve the feasibility of TIL ACT for solid tumors other than melanoma
will be delineated in subsequent chapters.
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1.3.2 Antigen-specific T cell therapy
The success of TIL ACT in melanoma has provided the impetus to improve upon the
therapy by improving the antigen-specificity, either through selection of antigen-specific T
cells or genetic engineering of T cells to express certain antigen-specific TCRs. The natural
starting place is to identify the specific T cells and their cognate antigens which mediate the
immune responses seen. TAAs typically fall under the category of either shared non-mutated
antigens, such as cancer testis antigens or differentiation antigens that are overexpressed in
cancers, or private neoantigens deriving from tumor mutations that are usually specific to the
individual’s cancer [121]. Early studies in melanoma identified two differentiation antigens,
MART-1 and gp100, that were well recognized by melanoma TIL [122, 123]. A clinical
study using T cells that were virally transduced with high-affinity TCRs for these antigens
showed cancer regression in several patients [124]. TCR-engineered T cell therapy has also
shown some success in a clinical trial for patients with melanoma (45% ORR; 5/11 patients)
and synovial sarcoma (66% ORR; 4/6 patients) with T cells targeting the cancer testes
antigen NY-ESO-1 [125]. However, targeting shared antigens can have sometimes serious
on-target off-tumor effects as they can be expressed in normal tissues also [125-127].
These potential issues have raised interest in targeting tumor-specific mutated
antigens and the emergence of next-generation sequencing has made this possible [128, 129].
Several retrospective studies of ACT TIL treated patients have identified neoantigen-reactive
TIL in the infusion products for melanoma, various epithelial gastrointestinal tumors, and
breast cancer [112, 114, 130]. It is unclear how much these TIL contributed to tumor
regression since they were not pure populations of antigen reactive cells, but it is likely they
played some part given the evidence that increased mutation load correlates with increased

31

survival in general as well as better response to CBI [131-134]. Further studies have also
identified TIL from patients that recognize antigens from driver mutations like TP53 and
KRAS in colorectal cancer, ovarian cancer, and pancreatic cancer [115, 135-137].
Interestingly, Eric Tran and colleagues at the NCI identified TIL from two different
colorectal cancer patients that recognized KRAS neoeptiopes restricted to the same MHCI
allele, hinting at the possibility of developing TCR-engineered T-cells targeting common
driver mutations across multiple tumor types [115].
In addition to finding antigen-specific T cells or TCRs at the tumor site, antigenreactive endogenous T cells (ETCs) can also be found circulating in the blood. These ETCs
can be isolated from peripheral blood and expanded ex vivo for ACT in a method called ETC
Therapy [138]. T cells specific for the melanoma associated antigens MART1, tyrosinase and
gp100 were observed in the peripheral blood of melanoma patients [139-141]. Technical
hurdles face ETC given that circulating antigen-specific T cells are often <0.1% of the
peripheral population, but techniques such as cell sorting with tetramers have allowed this
therapy to be translated into the clinic. To date, several ETC Therapy trials have been
conducted in melanoma patients [138]. While many of the studies demonstrated clinical
benefit (i.e. stable disease) and some patients experienced durable complete responses, the
ORR generally remained less than 25%. The only exception is a study by Khammari et al.
that reported a 43% ORR, which is comparable to the response rates reported for TIL ACT
[142]. While challenges still remain to improve ETC Therapy, it could eventually be
transposed to other cancer types as evidenced by a recent report that identified circulating
neoantigen reactive T cells in gastrointestinal cancer patients [143].

32

1.3.3 Chimeric-antigen receptor T cell therapy
In the effort to improve the antigen-specificity and function of adoptive transferred T
cells, genetically engineering them to express chimeric-antigen receptors (CARs) is the next
logical step. Endogenous CD8+ T cell activation by its cognate antigen relies on recognizing
it while bound to MHCI and also requires costimulation to help sustain the activation [1].
However, MHCI expression loss and lack of proper costimulation are two well-known
mechanism of immune evasion [1]. Additionally, TCR-affinity for shared TAAs can
sometimes be weak. As such, CAR-T cells, have been proposed as a way to overcome these
potential issues. CARs were pioneered in the late 1980s and essentially use a receptor that is
composed of an extracellular antigen-binding domain of an antibody that is linked to
intracellular signaling chains. These are typically the CD3-ζ chain from endongenous TCRs
stacked on top of costimulatory domains (e.g. CD28, 4-1BB, OX40) to provide complete
activation [144-146]. CARs can be easily transduced into patient T cells using viral vectors.
In this way, CAR-T can easily provide non-MHC–restricted recognition of cell-surface
TAAs.
Unfortunately, the same pitfalls with using endogenous TCRs specific for nonmutated public antigens can also apply to CAR-T [147]. This makes targeting these kinds of
cancer antigens that are also normally expressed on non-essential tissues an important
consideration to avoid serious toxicity. In fact, it is in this realm that CAR-T has seen
overwhelming success. Targeting B cell malignancies like acute lymphoblastic leukemia
with CD19-targeted CAR-T has produced complete response rates ranging from 70% to 91%
in children and adults [148]. In 2017, this led to a CD19-directed CAR-T (Kymriah) to being
not only the first cellular therapy approved by the FDA, but also the first treatment to include
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gene therapy. There are currently several more trials ongoing for other hematological
malignances using CAR-T against new antigen targets [148]. While blood cancers have
enjoyed remarkable response rates with CAR-T, the efficacy in solid tumors is still unclear.
So far, the only example of strong regression in solid tumors is in glioblastoma using CAR-T
targeting Interleukin-13 receptor alpha 2 [149]. Unfortunately, this patient recurred after
about 8 months. Several CAR-T trials in solid tumors are currently ongoing for prostate
cancer, mesothelioma, pancreatic cancer, glioma, glioblastoma, and sarcoma [148]. Several
CAR-T trials in solid tumors are currently ongoing for prostate cancer, mesothelioma,
pancreatic cancer, glioma, glioblastoma, and sarcoma [148].
CAR-T also suffers toxicities associated with cytokine release syndrome and
neurotoxicites, which are probably a result of patients being infused with a large amount of
activated T cells [147]. Finally, while there is also the issue of antigen loss being a
mechanism of immune escape since CAR-T only target one antigen, there are some
preclinical studies addressing this issue by using CAR-T multiple specificities [150].

1.4: Improvement of TIL-based Adoptive Cell Therapy
While TIL ACT has provided the best results for solid tumors in terms of cellular
therapy, there are still opportunities for improvement. The numerous preclinical and clinical
studies over the past 30 years have revealed several factors important the efficacy of TIL
ACT: (1) Generation of a clinically relevant number of TIL that are (2) enriched for antigenspecific TIL and (3) that display phenotypic characteristics that confer improved
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functionality and durable persistence. Previous work from our group and others has focused
on addressing these points so as to increase the scope and efficacy of TIL ACT.

1.4.1 Adding 4-1BB costimulation
Several TIL ACT trials for melanoma patients demonstrated that a high number of
total TIL infused, and in particular a higher amount of CD8+ TIL, is correlated with objective
response [108, 151, 152]. However, several studies have found inconsistent generation of a
large amount of CD8+ TIL from tumor fragments with high-dose IL-2 (6000 U/mL).
Reported success rates for general TIL growth range from 31-94%, although no consistent
cut-off number was used between studies [109, 153-155]. With regard to the TIL ACT
experience and MD Anderson Cancer Center, it was found that 40x106 cells were needed in
the initial expansion to confidently move forward to the expansion phase [156]. The reported
success rate with this cut-off was 62%. Likewise, the reported fraction of CD8+ TIL in the
initial expansion product or infusion product varied widely, although the overall average
CD8% was >50% [108, 152, 157, 158]. Finally, the time of initial TIL expansion phase
reported in these studies showed that it can last from 3-5 weeks. Tran et al. demonstrated that
the longer TIL remain in culture, the more differentiated they become (based on CD27 and
CD28 expression) and the shorter their telomeres [158]. Both of these characteristics have
been correlated with worse clinical response, TIL persistence, and proliferation [159-161].
Taken together, these identified shortcomings provided points of attack to improve
the quality of the TIL product generated. As such, 4-1BB costimulation provides a way to
address these points given the signaling pathway’s ability to improve the proliferation,
survival, and effector function of CD8+ TIL [53, 162-164]. 4-1BB signaling accomplishes
these results by activating the NF-κB and MAPK pathways, which are well-known regulators
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of cell survival, maturation, and proliferation (Figure 7) [165-168]. Ligation of 4-1BB, either
through interaction with trimers of its natural ligand 4-1BBL or through crosslinking with an
agonistic antibody, recruits TNFR-associated factor (TRAF) 1, TRAF2, and TRAF3 to its
cytoplasmic tail, which form heterotrimers themselves [169]. TRAF1 functions to sustain
TRAF2 expression and signaling while 4-1BB signaling seems to be dependent on TRAF2
participation [170]. TRAF2 has E3-ubiquitan ligase activity, acting as a scaffold for the
recruitment of factors that ultimately lead to the activation of NF-κB and MAPK signaling
[169]. Induction of 4-1BB signaling results in the secretion of IL-2 and IFN-γ, and the
expression of the anti-apoptotic proteins Bcl-xL and Bfl-1, which protect against activationinduced T-cell death [162, 163].
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Figure 7. 4-1BB signaling pathway.
When 4-1BB signaling is triggered in the T-cell, TRAFs are recruited to the cytoplasmic tail
in order to propogate signaling via the NFκΒ and MAPK/ERK pathways that ultimately
result in changes in gene expression geared towards pro-survival, proliferation, and effector
functions.
Previous work in the lab by Chacon et al. focused on the effects of integrating a fullyhuman agonistic 4-1BB monoclonal antibody (a4-1BB mAb) from Bristol-Myers Squibb
(Urelumab; BMS 663513) into the TIL expansion process. Addition of a4-1BB to the tumor
fragment culture (initial expansion phase) augmented and accelerated CD8+ TIL growth
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compared to using IL-2 only, which seemed to be helped by activation of DCs within the
tumor tissue [171]. This also resulted in increased tumor specificity, which is likely due to
the fact that 4-1BB costimulation targets and enriches for recently antigen-stimulated CD8+
TIL [53, 55, 172]. Furthermore, use of a4-1BB also protected TIL from activation-induced
cell death (AICD), to which they were previously found to be susceptible, after the second
large expansion phase [173]. Additionally, its use during the large expansion phase
maintained their CD28 expression which is correlated with longer telomeres [159, 171, 174].
The importance of 4-1BB costimulatory signaling has been corroborated by other
groups as well. CD28 is probably the most widely recognized costimulatory signal following
TCR activation. As such, most classical methods of expanding T cells in vitro involve antiCD3/anti-CD28 microbeads. However, these beads typically preferentially expand CD4+ T
cells instead of CD8+ T cells [175-177]. Furthermore, it has been reported that the 4-1BB
costimulation better expands memory, antigen-specific, CD8+ T cells than compared to
CD28 costimulation, which were mainly naïve cells [178]. Beyond improving proliferation
and cytotoxicity, 4-1BB costimulation also has more beneficial effects on T cell metabolism
as compared to CD28 signaling. Several studies have revealed that 4-1BB costimulation
results in metabolic reprogramming that involves mitochondrial enlargement, increased
mitochondrial respiratory capacity, and increased mitochondrial biogenesis [179-181]. These
alterations may ultimately improve T cell persistence and anti-tumor activity. Finally, 4-1BB
costimulation appears to impart lasting benefits that are mediated by epigenetic changes
[182].

38

1.4.2 Improving TIL product with gas-permeable culture flasks
Ways to improve TIL growth are not just limited to growth factors provided in culture
medium. Treating patients with ACT TIL can also be improved by the materials used and the
simplification of manipulating the cultures. The traditional TIL growth protocols use 24-well
tissue culture plates, various sizes of tissue-culture flasks, and gas-permeable bags [157]. Use
of novel gas-permeable flasks (GREX), which have a membrane on the bottom upon which
cells sit, have improved TIL expansion and simplified the logistics, thus making the process
more accessible [183, 184]. In addition to this important but oft over looked component, the
GREX flasks were also found to be beneficial for the TIL function and phenotype [185]. Due
to the position of the TIL on top of the gas-permeable membrane, the cells can take
advantage of the increased oxygen exchange. This resulted in rescue of TIL growth for
cultures that did not expand in the traditional flasks, maintenance of clonal diversity, and
improved mitochondrial function [185]. Furthermore, the GREX flasks also affected a
beneficial phenotypic change on the TIL as marked by increased fraction of CD8+BTLA+
TIL. BTLA, or B-and-T lymphocyte attenuator, is traditionally thought of as a negative
regulator on T cell function [186, 187]. However, a higher percentage of BTLA expressing
CD8+ TIL in the infusion product was correlated with persistence and response in TIL treated
patients [108]. Further work by Haymaker et al. and Ritthipichai et al. laid out respectively a
possible explanation for this by showing that, compared to CD8+ TIL lacking BTLA
expression, BTLA+CD8+ TIL are less differentiated (“younger”) and able to serially kill
cancer cells [188, 189].
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1.4.3 Genetic engineering of TIL to improve function
As our understanding of biological processes continues to improve, it’s likely that the
next generation of cellular therapeutics will involve genetic engineering. So far this is best
exemplified by the ground-breaking FDA approval of a CD19 CAR-T, not only the first
cellular cancer immunotherapy approved, but the first to involve genetic engineering.
Biological manipulation like this is not restricted to expression of chimeric-antigen receptors
or antigen-specific TCRs, but can also produce so called “armored” T cells that will be able
to resist or even exploit immunosuppressive signals as well as provide their own cytokine
stimulation.
Receiving supportive stimulation from cytokines is an important aspect of a sustained
immune response, with IL-2 being one of the most well-known T cell growth factors. Early
preclinical studies by Rosenberg and colleagues established that transduction of human T
cells with the IL-2 gene allowed prolonged persistence in vitro without exogenous IL-2 and
could produce their own IL-2 upon TCR activation [190, 191]. Based on this, TIL ACT with
IL-2 transduced TIL could be beneficial due to improved persistence in vivo [192]. Other
promising cytokines have been explored as well, like IL-12 and IL-15, due to their effector T
cell proliferative and protective abilities [193-196]. Being able to provide local
administration of lymphoproliferative cytokines could help overcome suppression in the
TME as well as avoid toxicities associated with systemic cytokine administration [197, 198].
There have also been efforts to improve T cell anti-tumor activity via expression of
non-endogenous receptors. In melanoma, ACT with TIL expressing the CXCR2 chemokine
receptor could allow for better trafficking to tumors due to their expression of the CXCR2ligands CXCL1 and CXCL8 [199, 200]. Once there, improved activity could be endowed by
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incorporation of dominant-negative receptors (lack intracellular signaling domains) for TGFβ or Fas, thus resisting immunosuppression of apoptosis respectively [201-203]. A method to
expand genetically engineered TIL for ACT has been established and will facilitate future
studies of this type [204].

1.5: Main Theoretical Questions
The success of CBI has reinvigorated the cancer therapy field, particularly for
advanced melanoma which has double the survival rates compared to 20 years ago [16, 205].
Prompted by this, the race to expand treatment to other cancer types is in full swing. Several
tumor types have received great benefit (e.g. NSCLC, RCC, MSI-Hi), but they often belong
to the same category of being highly immunogenic and/or being immune-inflamed [206208]. Unfortunately, there are many more solid tumor types (e.g. pancreatic, ovarian, breast,
MSS colorectal, prostate cancer) that fall on the other end of the spectrum and in which CBI
has been ineffective so far. Given the heterogeneity of cancers, the immune contexture of
some cancer may not be conducive to CBI and instead that might benefit from
immunotherapies that approach the issue from another angle. Despite the lack of efficacy of
immunotherapy so far, there is still evidence for the role of TIL in control of these tumors
[27]. Given this fact coupled with the success of TIL ACT, which can take advantage of
antigen-specific TIL by expanding them ex vivo, I sought to assess the feasibility of this
therapy in other solid tumors that still have an unmet need.
One such tumor type is pancreatic cancer. Several immunotherapy trials, CBI or
otherwise,

have

failed

to

provide

improved
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clinical

benefit

compared

to

surgery/chemotherapy, which remain the standard of care [77, 209-213]. As such, the 5-year
survival rate remains the lowest of any cancer type at <10% [16]. In contrast to melanoma,
pancreatic cancer TME is characterized by an extensive stromal compartment composed of
immunosuppressive immune cells and a fibrotic extracellular matrix [214, 215]. In spite of
this seemingly restrictive immune TME, the presence of TIL is correlated with increased
survival [85, 216]. Therefore, I investigated transposing TIL ACT to pancreatic cancer with
the following hypothesis and specific aims to guide me:
Hypothesis: Tumor-specific TIL exist in solid tumors beyond melanoma and their potential
for tumor clearance can be harnessed through TIL-based Adoptive Cell Therapy.
I.

Specific Aim 1: Determine the immune and molecular landscape of TIL in pancreatic
cancer (PDAC) and ovarian cancer (OvCA)

II.

Specific Aim 2: Elucidate requirements for TIL expansion in PDAC and OvCa, and
determine phenotypic attributes of the expanded TIL

III.

Specific Aim 3: Interrogate the presence of tumor-reactive TIL in TIL generated
from tumors generally unresponsive to current immune checkpoint blockade therapy
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Chapter 2: Materials and Methods

Patient selection
Pancreatic Cancer Samples. After obtaining written informed consent, 61 patients
with primary or metastatic pancreatic ductal adenocarcinoma underwent surgical resection.
Patients are referred to by their de-identified “MP” number. Tissue from surgical resections
was used to expand TIL under protocols (PA15-0176, LAB00-396, PA15-0014 for PDAC
samples and LAB06-0755 for melanoma samples) approved by the Institutional Review
Board of The University of Texas MD Anderson Cancer Center.
Ovarian Cancer Samples. Patients with primary or metastatic high-grade serous
ovarian carcinoma underwent surgical resection (n=98, 84 evaluable for flow cytometry). In
47 patients, platinum-based chemotherapy and/or chemoradiation was administered. Patients
are referred to by their de-identified number. Informed consent was obtained from all
individual participants included in the study for their specimens and data to be used in
research and for publication.
Ethical approval and tissue from surgical resections used to expand TIL were both obtained
under protocol (PA16-0912 and LAB02-188) approved by the Institutional Review Board of
The University of Texas MD Anderson Cancer Center.

Reagents and cell lines
A fully human and purified IgG4 monoclonal antibody (mAb) against human
CD137/4-1BB, Urelumab (663513), was kindly provided by Bristol-Myers Squib (BMS).
Human recombinant interleukin-2 (IL-2) (ProleukinTM) was generously provided by
Prometheus Therapeutics & Diagnostics. MHC class I blocking antibody (clone W6/32) and
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isotype control (mouse IgG2a, clone eBM2a) were purchased from Invitrogen and
eBioscience, respectively. Autologous pancreatic tumor targets were found to match the
patients using STR DNA fingerprinting performed at MDACC and the tumoroid was
confirmed mycoplasma-free. CAPAN-1 and SKOV3 cell lines were purchased from ATCC.
COV318 and COV362 were purchased from Sigma-Aldrich (now Millipore-Sigma, St.
Louis, MO). All cell lines were HLA-typed, STR fingerprinted, and confirmed mycoplasmafree at MDACC.

Isolation and expansion of TIL from human solid tumors
The tumor samples were cut into 1-3 mm2 fragments and placed in TIL culture media
[TIL-CM: RPMI-1640 with GlutaMax (Gibco/Invitrogen), 1× Pen–Strep (Gibco/Invitrogen),
50 μmol/L 2-mercaptoethanol (Gibco/Invitrogen), 20 μg/mL Gentamicin (Gibco/Invitrogen),
and 1 mmol/L sodium pyruvate (Gibco/Invitrogen] with 6000 IU/ml IL-2 in 24-well plates
for up to 5 weeks, as previously described [108, 217]. The same method was applied for the
metastatic melanoma samples. For the 4-1BB mAb (a41BB) condition, both 6000 IU/ml IL-2
and 10 ug/ml 4-1BB mAb were added in the culture plates on day 0 and day 4 or 5. TIL were
expanded for up to 35 days prior to performing the described assays or the rapid expansion
protocol (REP). For the IL-2+OKT3+a41BB condition, five tumor fragments were put in a
G-Rex 10 flask (Wilson Wolf Manufacturing, New Brighton, MN) in 20 mL TIL-CM with
6000 IU/mL IL-2, 10 ug/mL 4-1BB mAb, and 30 ng/mL anti-CD3 (OKT3) as previous
described [218]. Four to five days after culture initiation, 20 mL of additional TIL-CM with
6000 IU/mL IL-2 was added. Half-media changes were done every 3-4 days with fresh TILCM containing 6000 IU/mL IL-2 for up to 35 days or until the cells formed a thick layer
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completely covering the bottom of the flask. The cell suspensions were collected and
cryopreserved for later testing.

Cell Sorting and Rapid Expansion of CD8+ OvCa TIL
To control for reactivity of CD8+ TIL, bulk TIL products were stained with CD3
FITC, CD8 APC-H7, and SYTOX Blue Dead Cell Stain in order to isolate the CD8+ T cells
using a BD FACSAria IIIu in the MD Anderson Cancer Center (MDACC) Flow Cytometry
and Cellular Imaging Core Facility. Then, to provide greater cell numbers for functional
assays, the sorted CD8+ TIL underwent the rapid expansion protocol in G-Rex10 flasks,
which was previously described by Forget et al. and then viably-frozen [217]. Briefly, the
REP was performed in the G-Rex 10 device (Wilson Wolf Manufacturing) following a
scaled-down version of the previously described protocol [217]. Briefly, TIL were put in
culture with pooled allogeneic irradiated PBMC feeder cells at a ratio of 1 TIL to 200 feeders
in combination with 6000 IU/ml IL-2 and 30 ng/mL of anti-CD3 (OKT3 clone) on day 0 of
the REP. The REP process lasted for 14 days, with REP-CM (half TIL-CM and half AIM-V
(Invitrogen)) used for the first 7 days and only AIM-V for the last 7 days of expansion. The
cells were collected and cryopreserved for later assays.

Immunohistochemistry (IHC)
Four-micrometer-thick serial sections were obtained from representative formalinfixed, paraffin-embedded (FFPE) blocks for IHC, as well as hematoxylin and eosin (H&E)
staining. H&E slides were examined by a pathologist to confirm the presence of tumor. IHC
was performed using a Leica Bond Max automated staining system (Leica Microsystems)
with antibodies against CD3 (dilution 1:100; Dako). The expression of the marker was
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detected using a Leica Bond Polymer Refine Detection kit (Leica Microsystems)
with diaminobenzidine reaction to detect antibody labeling. Counterstaining was done using
hematoxylin. Human tonsil FFPE tissues with and without CD3 primary antibody were used
as positive and negative controls, respectively. For quantification of CD3 expression, the
slides were digitally scanned at 200 magnification using the Aperio AT2 scanner (Leica
Microsystems). The images were visualized using the ImageScope software (Leica
Microsystems) and analyzed using the Aperio Image Toolbox (Leica Microsystems). Five
regions of interests were randomly selected within the tumor area of each slide. The
number of CD3 positive cells per mm2 (cell density) was evaluated, and the final score was
expressed as the average density of the five areas.

Flow Cytometric Analysis of TIL
Fresh tumor samples were manually disaggregated between frosted-glass slides to
obtain a single-cell suspension for analysis. Both the disaggregated tissue samples and
expanded TIL were blocked in FACS Wash Buffer (Dulbecco’s Phosphate Buffered Saline
1X with 1% Bovine Serum Albumin) supplemented with 5% goat serum (Sigma-Aldrich) for
10 min at room temperature. Cell suspensions were then stained in FACS Wash Buffer for 30
min using fluorochrome-conjugated monoclonal antibodies for CD3, CD4, CD8, CD16,
CD56, CD57, Granzyme B, TBET, γδ TCR, CD27, CD28, CD45, CD45RA, CD45RO,
CCR7, CD103, CD152/CTLA4, BTLA (clone J168) (BD Bioscience), CD25, CD279/PD-1,
KLRG1, CD278/ICOS, CD366/TIM3 (Biolegend), and CD223/LAG3, FoxP3, Ki67,
CD357/GITR, Eomes (eBioscience/ThermoFisher). Stained cells were fixed in 1%
paraformaldehyde solution for 20 min. Intracellular staining was performed using
eBioscience transcription factor staining kit according to the manufacturer’s instructions.
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Samples were acquired using the BD FACSCanto™ II or BD LSRFortessa X-20 and
analyzed using FlowJo Software v10.2 (Tree Star). Dead cells were excluded using an
AQUA or Yellow live/dead staining (Invitrogen).

T-cell Receptor Beta Sequencing
Genomic DNA was extracted from samples using DNeasy Blood & Tissue Kit
(Qiagen) as per manufacturer’s instructions. TCRβ CDR3 regions were amplified from
between 0.2–3 μg of DNA. All samples had the ImmunoSEQTM assay performed at Adaptive
Biotechnologies, with deep sequencing for PBMC DNA and survey-level sequencing for all
others. Data analysis was performed at MDACC.

Preparation of Single-Cell RNA Sequencing Libraries for PDAC TIL
Fresh tumor samples were disaggregated using a MediMachine (BD Biosciences) to
create a single-cell suspension. After disaggregation, CD3+ T cells were isolated for
sequencing via magnetic bead separation using the EasySepTM Release Human CD3 Positive
Selection Kit (StemCell Technologies) according to the manufacturer’s instructions. For
cultured TIL, previously cryopreserved samples were thawed, washed with PBS, and
resuspended at 1x106 cells/mL. The single-cell RNA sequencing libraries were prepared
according to the protocol for the 10x Genomics ChromiumTM Single-cell V(D)J Regent Kits
using the v1 chemistry. T cells were loaded on a Chromium single-cell A chip and placed in
a Chromium controller where they were partitioned into single-cell droplets to undergo cell
barcoding and cDNA synthesis. After isolation of the cDNA by DynaBeads MyOne Silane
beads, it was then PCR amplified, again purified by size-selection using SPRIselect
(Beckman), all according to the manufacturer’s instructions. For construction of the gene
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expression library, 50 ng of amplified cDNA was fragmented, end repaired, sized-selected
using SPRIselect and PCR amplified again according to the manufacturer’s instructions. For
the TCR library, 2 ul of amplified cDNA was used for enrichment of TCR transcripts via the
Chromium Human T cell V(D)J Enrichment Kit and purified using SPRIselect, both
following the manufacturer’s instructions.

Sequencing of the TCR and gene expression libraries
The transcriptome libraries were pooled and sequenced paired-end (26 cycles read 1,
91 cycles read 2, 8 cycles i7) on the Illumina Novaseq to a targeted depth of 600M pairedend reads per library. TCR libraries were pooled and sequenced on the Illumina Miseq 150bp
paired-end to a targeted depth of 1000 reads per T-cell.

Unsupervised clustering of scRNAseq data
The Seurat package version 2.4 workflow in R (https://github.com/satijalab/seurat)
was used for transcriptome processing/clustering plots. The data was integrated for batch
correction using the first 50 canonical components. To separate CD8 and CD4 cells, each cell
was scored for expression of genes over expressed in clearly CD8 or CD4 cells (by CD8A,
CD4 transcript count). Cells were then assigned to the group where they had the higher score
and then split for further processing. The tSNE embedding and clustering was performed on
the first 20 principal components of the integrated embedding. The cells were clustered using
shared nearest neighbors (SNN) and the heat maps represent the top over expressed genes of
each cluster selected by average fold change and p-value on a Wilcox test. Clusters were
named by picking one gene indicative of their functional status. The Circo plots were
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generated using a custom code where the inner tree is hierarchical clustering of the mean of
the transcriptome data for each clonotype. The shared clones between the fresh and grown
TIL were matched via their TCRa and TCRb nucleotide sequence and then graphed based on
the relative frequency in each sample.
TIL Recognition Assays via 4-1BB Upregulation and IFN-γ secretion
For the PDAC TIL: In triplicate, T cells were put at a 10:1 ratio with their autologous
tumor target, CAPAN-1 (HLA mismatch control), or media (TIL alone). For some
experiments the autologous tumor targets were incubated with 80 µg/ml of anti-MHC class I
antibody (clone W6/32) for 3h prior to addition of T cells, as previously described [219].
After 24 h incubation, the supernatants and T cells were collected. TIL were analyzed for 41BB/CD137 expression via flow cytometry. Detection of secreted cytokines in the
corresponding supernatants were detected using a V-PLEX Plus Proinflammatory Panel 1
(human) kit and analyzed on a QuickPlex SQ 120, both available from Meso Scale
Discovery. Reported values have CVs <20%.
For the INF-γ ELISPOT: One day prior to the assay, the TIL were thawed and rested
overnight in TIL-CM with 6000 IU/mL IL-2. Six hours prior to the assay, TIL were washed
and rested in TIL-CM without IL-2. The tumor lines were put at 1x106 cells/mL and
incubated with 80 μg/mL of the HLA-ABC blocking antibody or 80 μg/mL of its isotype
control for 3 hrs in 15 mL conical tubes at 37C. The tumor cells were then added directly to
the ELISPOT plate. TIL were then put at a 2:1 or 4:1 ratio with an HLA-matched OvCa cell
line (either SKOV3, COV318, or COV362) in the presence of an HLA-ABC blocking
antibody, its isotype control, PMA/Ionomycin, or media (TIL alone). The conditions were
performed in triplicate and the cells were co-cultured for 15 hrs before developing as
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previously described [220]. Spots on ELISPOT plates were counted with the ImmunoSpot
machine (Cellular Technology Ltd., Shaker Heights, OH).

Statistical Analysis
GraphPah Prism v7.0 (GraphPad Software) was used for graphing and statistical
analysis. Differences between groups or experimental conditions were determined using
either parametric or non-parametric, two-tailed t-tests (paired or unpaired as appropriate).
Linear regression and Spearman correlation analyses were also used as indicated. Two-sided
p-values <0.05 were considered statistically significant and in the figures are indicated as *
p<0.05, ** p<0.01, *** p<0.001, and **** p<0.0001.
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Chapter 3: 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth In to a
Distinct Repertoire Capable Of Tumor Recognition in Pancreatic Cancer
This chapter is based on the original research article “4-1BB Agonist Focuses CD8+ TumorInfiltrating T-Cell Growth In to a Distinct Repertoire Capable of Tumor Recognition in
Pancreatic Cancer” published by Sakellariou-Thompson et al. in Clinical Cancer Research
on September 25th, 2017 (DOI: 10.1158/1078-0432.CCR-17-0831). It is presented with
permission from the American Association for Cancer Research (AACR) as per item 4 of the
“Article Reuse by Authors” section of the publisher’s Copyright, Permission, and Access
document which states, in part:
“Authors of articles published in AACR journals are permitted to use their
article or parts of their article in the following ways without requesting
permission from AACR: Submit a copy of the article to a doctoral candidate’s
university in support of a doctoral thesis or dissertation.”

3.1 Introduction
Pancreatic cancer is the third-highest cause of cancer-related death for men and
women in the United States and is expected to become the second-leading cause of cancer
mortality by 2030 [221, 222]. The majority (85%) of pancreatic cancer diagnoses are
classified as pancreatic ductal adenocarcinoma (PDAC) [223]. Patients afflicted with PDAC
often present with late-stage cancer and face the poorest prognosis of all cancer types with a
5-year survival rate of around 6% [224]. Despite efforts to improve treatment, surgery,
chemotherapy, and radiation remain the only options. These treatment strategies have shown
limited effectiveness as most patients will recur within a year of treatment even after
successful tumor resection [224, 225]. Therefore, there is a great need to broaden treatment
options.
Immunotherapy has made a tremendous mark in the treatment of cancer, especially in
the past decade. Its success was first observed in the treatment of metastatic melanoma with
high-dose IL-2 and then more recently with agents that block CTLA-4 and PD-1 (checkpoint
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blockade) [43, 226, 227]. These treatments were later transposed to several cancer types,
including MSI-high cancers regardless of indication [134, 228-235]. In PDAC, however, they
have been ineffective with no objective response seen with the exception of the very rare
MSI-high subtype of PDAC [209, 210, 231]. The lack of efficacy could be a result of the
paucity of CD3+ T-cell infiltrate [236]. An alternative approach to overcome the limitation
posed by the modest immune infiltrate in PDAC is the ex vivo amplification of TIL for reinfusion through autologous ACT.
TIL ACT expands T cells up to several hundred-fold from surgically resected tumor
and re-infuses them into the patient, providing a large influx of anti-tumor T cells. Our group
and others have demonstrated its effectiveness in melanoma [94, 108, 237, 238]. With an
average objective-response rate (ORR) of 50%, TIL ACT is among the best treatment options
for metastatic disease. The MDACC experience also demonstrated a positive correlation
between CD8+ TIL infused and response [108]. These results have already spurred efforts to
translate ACT to other cancer types, and a handful of preliminary studies have reported
encouraging data in small cohorts of patients in indications such as cervical cancer (33%
ORR), ovarian cancer (avg PFS 3.7 months; Pederson Oncoimmunol 2018) and
gastrointestinal malignancies (case studies reported but no ORR yet) [239, 240]. PDAC could
also potentially benefit from TIL ACT as the presence of CD8+ TIL is associated with greater
5-year survival [85, 216]. This suggests that endogenous PDAC TIL can exert some degree
of tumor control, supporting the potential of TIL ACT.
One of the major challenges faced in growing TIL from GI cancer types for ACT
trials is the difficulty of expanding CD8+ T cells from the tumor tissue [119, 241]. PDAC has
a well-characterized immunosuppressive tumor microenvironment that might contribute to
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the difficulty of triggering the proliferation of cytotoxic CD8+ T cells from this tumor tissue
and account for their decreased numbers [236, 242]. A method to resolve this barrier is by
manipulating 4-1BB/CD137, a member of the tumor necrosis factor receptor family, which
provides a strong co-stimulatory signal for increased activation, proliferation, and survival.
This receptor is predominantly expressed on recently activated CD8+ T cells with peak
expression at 24 h [55]. In fact, our group demonstrated that inclusion of an agonistic 4-1BB
mAb (Urelumab, BMS) in TIL cultures was able to increase melanoma and triple-negative
breast cancer CD8+ TIL proliferation [220, 243]. Based on this previous work, we posited
that use of an agonistic 4-1BB mAb in PDAC TIL culture would provide the same benefits of
increased CD8+ TIL yield.
Here, we demonstrate that the addition of an agonistic 4-1BB mAb increases the
ability to grow TIL from PDAC, improves the total yield, and stimulates the proliferation of
more CD8+ T cells without overly differentiating them. In addition, these CD8+ TIL have a
distinct TCR repertoire compared to IL-2 only grown TIL and display MHC class I-restricted
autologous tumor recognition. These results support the use of 4-1BB-expanded TIL in ACT
strategies for patients with PDAC.

3.2 Results
3.2.1: PDAC TIL infiltrate is predominantly CD4+ T-cells
To determine if the immune component of PDAC was sufficient for TIL ACT, we
assessed the immune infiltrate by performing flow cytometry on manually disaggregated
samples (n=28). The amount of CD3+ TIL observed was less than 1% of all cells in the tumor
sample on average as compared to metastatic melanoma with an CD3+ TIL infiltrate >2%
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(Figure 8A). Quantitative IHC analysis found that the mean density of CD3+ TIL was 314
cells/mm2 (Figure 8B). This is fewer than what the literature reports for an immunogenic
cancer like melanoma (422 cells/mm2) [244]. Additionally, metastatic (closed circle) and
primary (open circle) PDAC samples did not appear to stratify. Further IHC analysis showed
that all samples displayed ≥50% MHC Class I expression that was homogenous throughout
the tumor tissue, suggesting that lack of Class I was not the reason for low CD3+ infiltration
(Figure 8C). We also evaluated the proportion of CD8+ and CD4+ T cells. With an average
CD8:CD4 ratio of 0.75, CD4+ TIL comprised the majority of the T-cell infiltrate (Figure 8D).
As a point of comparison, metastatic melanoma showed a CD8:CD4 ratio of 1.5 (Figure 8D).
This ratio is similar to IHC data also from Erdag et al. that exhibited a CD8:CD4 ratio of 1.6
[244]. Metastatic and primary sites did not seem to show a difference in CD8:CD4 ratio.
Phenotypic analysis on the CD8+ T cells determined their activation and differentiation state
by assessing their expression of CD28 (50% ± 20%), CD45RA (10% ± 6%), PD-1 (45% ±
12%), and BTLA (20% ± 12%) (Figure 8E). There were not enough primary samples that
could be compared with metastatic samples to discern a difference in the phenotype of their
TIL. However, the low frequency of CD45RA expression combined with expression levels of
the other three markers suggests a relatively activated and not terminally-differentiated
immune infiltrate.

54

Figure 8. PDAC TIL infiltrate is largely dominated by CD4+ T cells.
(A) Flow cytometry analysis was performed on freshly disaggregated tumor samples. A
representative figure showing the gating strategy based on CD3 and live/dead is presented on
the left. The right graph shows a significantly lower CD3+ immune infiltrate in PDAC as
compared to metastatic melanoma. (B) IHC analysis quantified the amount of CD3+
infiltration in PDAC. (C) IHC analysis showed that >75% of the PDAC tumor tissue
expresses MHC class I demonstrating HLA Class I expression. (D) CD8/CD4 ratio in fresh
PDAC sample compared to melanoma. (E) Phenotypic analysis of expression of CD28,
CD45RA, PD1, and BTLA on CD8+ TIL present in fresh samples.

3.2.2: PDAC shows an enriched T-cell repertoire in the tumor
Enrichment of T-cell clones at the tumor site in comparison to the blood would
suggest that the patient is mounting an immunogenic response to its tumor and that specific
T-cell clones are migrating to the tumor and proliferating in the tissue. To determine the
tissue-specific distribution of the T-cell repertoire, we sequenced the T-cell receptor beta55

chain (TCRB) CDR3 region of the T cells present in the blood, tumor and normal tissue from
seven patients when available (Figure 9). This analysis, presented as productive clonality,
revealed that the T-cell repertoire in the tumor is generally more clonal than in the blood
(Figure 9A). Productive clonality is a measure of the degree to which one or several unique
clones dominate the repertoire [245]. Linear regression analysis compared the relative
frequencies of individual TCRB clones present in both the blood and the tumor (Figure 7B).
All autologous blood-tumor pairs displayed slopes (m) <1, demonstrating a higher frequency
of shared clones in the tumor than the blood. However, it is possible that high frequency
clones present in the blood may correlate with high frequency clones present in the tumor. To
determine the strength of correlation between clones in these sites, clones were partitioned
and compared as follows using Spearman correlation: top clone frequency defined as ≥
0.24% in the tumor (red circles), remaining clones partitioned in half with mid-frequency
shared clones (green circles) and low-frequency shared clones (blue circles). Interestingly,
Spearman correlation analysis showed weak or undefined correlation between the frequency
of T-cell clones in the blood and their frequency in the tumor tissue (rs <0.5), even among
the top ranking clones in the tumor (red circles). Additionally, there were a few instances
where the middle-ranking clones in the tumor (green circles) had greater correlation with
their frequencies in the blood. Only MP31 showed good correlation (rs = 0.61) of the
frequencies of these top shared clones (Figure 9B). Linear regression analysis was also used
to compare the relative frequencies of individual TCRB clones present in both the normal
and tumor tissue (Figure 9C). Similar to the tumor-blood pairs, the slopes for all the tumornormal tissue pairs were <1, indicating that individual shared clones were found at higher
frequencies in the tumor than the normal. In addition, clones were partitioned and correlation
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calculated in the same manner as described above. In contrast to the tumor-blood pairs, the
frequencies of the T cells in autologous tumor-normal tissue pairs showed stronger
correlation among the top and mid-frequency clones. Four of the five pairs (MP64B, MP75,
MP81, and MP84B) had rs > 0.44 while two of them (MP64B and M75) had rs > 0.5,
showing that the repertoires were very similar between the tumor and the normal tissue in
these cases. Also different from the tumor versus blood comparison was that the top clones in
the tumor (red circles) were often high ranking in the normal tissue as shown by clustering
along the hashed line. MP31 shared very few clones overall, so it was not partitioned.
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Figure 9. TCRB clonality and frequency of shared TCRB clones higher in tumor
than autologous blood and normal tissue.
CDR3 sequencing of the TCR beta-chain was done on the blood, tumor and normal tissue.
(A) TCRB clonality is higher in the tumor than the blood for most samples. (B) Frequencies
of shared clones in the tumor and blood and (C) tumor and normal tissue are shown. Top Tcell clones from the tumor that are also shared between the blood or normal tissue are
highlighted in red. The remaining shared clones are split in half with the top half colored
green and the bottom half colored blue. Shared clones (n), linear regression analysis with line
of best fit (solid line), slope of best-fit line (m), and color-coded Spearman correlation
coefficient (rS) for each group are next to each graph in (B) and (C). Hatched lines represent
the identity line, i.e. 1:1 frequency ratio. The data plotted in (B) and (C) was jittered to
prevent over-plotting.

3.2.3: 4-1BB mAb increases total TIL growth, success rate, and frequency of CD8+ TIL
Prior work by our group detailed how infusion of melanoma patients with a higher
proportion of CD8+ T cells and larger amount of TIL in general correlated with better clinical
response [108]. This result coupled with our observations of a predominance of CD4+ TIL
and relative scarcity of CD3+ infiltration in general prompted us to consider ways to generate
greater TIL growth that was rich in CD8+ T cells. Previous work showed that recently
antigen-activated CD3+CD8+ TIL upregulate expression of the costimulatory molecule 41BB [55]. Furthermore, additional work by our group and others demonstrated that
stimulation of this pathway through the use of an agonistic anti-4-1BB (a4-1BB) antibody
could decrease time of TIL culture while increasing total TIL growth, particularly that of
CD3+CD8+ T cells [241, 243]. Thus we set up samples for TIL culture where one set of
fragments received only the conventional high-dose IL-2 (n=28) and the other received highdose IL-2 plus the a4-1BB mAb (n=27) (Table 1). The addition of a4-1BB increased the
average total TIL growth from 40x106 cells for IL-2 alone to 100x106 for IL-2 + a4-1BB
(Figure 10A). Only cultures that grew in at least one of the two conditions are represented in
Figure 10A. Additionally, a4-1BB doubled the success rate (14/27; 52%) for TIL growth
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from fragments compared to IL-2 only (8/28; 29%) (Table 2). The benchmark for a
successful TIL culture, 12x106 total cells, was established from scaling down the MDACC
Clinical Melanoma TIL Lab’s criterion for success where 20 fragments are set up for TIL
expansion and 40x106 cells is considered the minimum to treat a patient. Some IL-2 only
cultures did not reach the benchmark and several produced no discernible TIL growth while
their companion a4-1BB culture produced ≥12x106 cells (Table 1). To that effect, our work
demonstrates that use of a 4-1BB mAb could rescue cultures that would not have grown
under the conventional methods.
Next, we determined whether the cells that grew out of the cultures treated with a41BB were enriched for CD3+ TIL and if CD8+ TIL now comprised the majority of CD3+ T
cells. In cultures treated with a4-1BB, the total number of CD3+ TIL was significantly
increased over IL-2 only cultures on average from 30x106 cells to 75x106 cells respectively
Table 1. TIL from PDAC are mainly CD4+ but a4-1BB switches majority to CD8+
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(Figure 10B). Only cultures that grew in at least one of the two conditions are represented in
Figure 10B. Since NK cells and γδ TCR+ T cells can also express 4-1BB, we stained for their
presence in primary cultures to determine if the a4-1BB antibody being used was stimulating
their growth [246, 247]. Indeed we found that three cultures with a4-1BB were enriched with
a CD3-CD56+ population that was a greater proportion of the culture than CD3+ TIL (Figure
10C). Likewise, some cultures also showed an increase in γδ TCR+ T cells in a4-1BB
cultures versus IL-2 alone (Figure 10D, top graph). Only cultures that grew in both
conditions are represented in Figure 10C and D. Neither the increase in NK cell growth (p =
0.203) or γδ TCR+ T-cell growth (p = 0.078) due to 4-1BB co-stimulation was found to be
significant overall. However, co-stimulation with a4-1BB produced a primary TIL culture
that was on average 55% CD3+CD8+ TIL and 5% CD4+ TIL. We observed the opposite
situation in IL-2 alone cultures where 25% of CD3+ TIL were CD8+ and 60% were CD4+.
Overall, the 4-1BB mAb caused a dramatic switch in the composition of CD3+ TIL towards
the more favorable CD8+ TIL (Figure 10D).

Table 2. Using a4-1BB increases clinically relevant growth success rate.
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Figure 10. High numbers of CD8+ TIL can be expanded from PDAC with the use of
agonistic anti-4-1BB antibody.
Tumor fragments were set up with either high dose of IL-2 alone or with the addition of an
agonistic anti-4-1BB (a4-1BB). (A) Total TIL numbers and (B) total CD3+ TIL expanded
with or without a4-1BB. Expansion was considered successful with 12x106 cells or more
(dotted line); cultures which did not reach this number in both conditions are not presented.
(C) Percentage of CD3+ and CD3- CD56+ TIL grown in each condition. Only cultures with
successful growth in both conditions are presented. (D) Percentage of  TCR+, CD8+, and
CD4+ within the CD3+ T cell subset. Only cultures with successful growth in both conditions
are presented.
3.2.4: Addition of 4-1BB mAb does not overly differentiate CD8+ TIL
To better understand what effect the augmented growth via 4-1BB mAb stimulation
had on CD8+ TIL differentiation, we performed phenotypic analysis of CD28, CD45RA, PD1, and BTLA expression. Between IL-2 only and a4-1BB cultures, the only significant
change was a decrease in CD45RA expression (p = 0.031) (Figure 11A). In fact, the level of
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expression of these markers was comparable to that seen on CD8+ TIL in the fresh tumors
(Figure 6E). Further phenotyping was done using the established memory markers CD45RA,
CD27, CD28, and CCR7 (Figure 11B) [248]. The vast majority of TIL, regardless of culture
condition, were CD45RA-CCR7-, indicating that they are effector memory (EM) cells.
Further characterization of their EM status was done by analyzing differential expression of
CD27 and CD28, which has been shown to subdivide EM cells into four subsets termed
EM1, EM2, EM3, and EM4 (Figure 11C) [249].The majority of TIL, again regardless of
culture condition, fell in the EM3 (CD27-CD28-) subset which Romero et al. have shown to
display stronger cytolytic activity [249]. We also further explored the degree of
differentiation with the expression of KLRG1, CD57, Eomes, T-bet and Granzyme B. As
shown in Figure 12, KLRG1 was absent from both culture conditions. Combined with the
other markers, this supplementary analysis further testifies that the stimulation of 4-1BB does
not overly differentiate the cells and leads to the proliferation of effector/memory. Overall,
this shows that even though a4-1BB stimulates aggressive expansion of activated CD8+ TIL,
they do not become overly or terminally differentiated.
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Figure 11. Addition of a4-1BB does not overly differentiate CD8+ TIL.
(A) Percent expression of phenotypic markers (CD28, CD45RA, PD1 and BTLA) for T-cell
activation and differentiation on CD8+ TIL post-culture evaluated by flow cytometry. (B)
Comparing expression of CD45RA and CCR7 shows whether TIL are naïve (N), central
memory (CM), effector memory (EM), or terminally differentiated effector memory that reexpress CD45RA (TEMRA). (C) Comparison of CD27 and CD28 expression shows EM
subsets of CD8+ TIL grown in each culture condition. Representative dot plots for B and C
are shown on the right.
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Figure 12. Addition of a4-1BB does not lead CD8+ TIL into senescence.
Percent expression of phenotypic surface and intracellular markers (KLRG1, EOMES,
TBET, CD57 and GRZB) for T-cell effector/memory status of CD8+ TIL post-culture
evaluated by flow cytometry.
3.2.5: Expansion of distinct CD8+ T-cell clones favored by a4-1BB mAb compared to IL-2
alone
Next, we questioned how the culture conditions affected the repertoire of the TIL that
grew out by sequencing the TCR of sorted CD8+ T cells and comparing their relative
frequencies to each other and to their starting frequency in the tumor (Figure 13). Many
clones are shared (red lines) between the tumor and both TIL culture conditions. However,
these clones are present at different frequencies between the conditions, as demonstrated by
the position of the lines where further away from center denotes higher frequency. This
shows that the addition of a4-1BB mAb favors expansion of unique clones as compared to
IL-2 alone. This is further suggested by the presence of several T-cell clones that are shared
between the tumor and only one of the culture conditions (blue lines). Finally, sequencing
detected some clones that were not present in the tumor but were either present in only one
culture (black lines) or shared only between the two culture conditions (green lines). Overall,
in 4/5 patients, the addition of a4-1BB mAb in the culture expands a greater number of CD8+
TIL but focuses their repertoire as evidenced by the smaller number of TIL clones in the a41BB cultures than the IL-2 alone cultures.
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Figure 13. Distinct TCR repertoires are favored in each culture condition.
CDR3 sequencing of the TCR beta-chain was done on the blood, tumor and expanded TIL
(CD8+ sorted). Relative frequency in each sample is indicated along each axis of the hive
plot with frequency increasing away from the center. Red lines indicate TCRB clones shared
between all three samples, blue lines for those shared between one culture condition and the
tumor, green for those shared only between the culture conditions and finally black lines
indicate TCRB clones found in only one condition. Total TIL grown and number of unique
clones in each condition are shown.

3.2.6: PDAC CD8+ TIL recognize autologous tumor targets
Given the distinct repertoire generated by each culture condition, the anti-tumor
potential of both IL-2 only and IL-2 + a4-1BB cultured PDAC CD8+ TIL was assessed. To
this end, sorted CD8+ TIL lines from both conditions were rapidly expanded (REP) and cocultured for 24 h with autologous tumor targets derived from patients MP81 and MP64B
(Figure 14). Bulk TIL initially expanded using a4-1BB in combination with IL-2 were also
put through the REP process and achieved the expected fold expansion (500x – 1500x) after
14 days, confirming that both sorted CD8+ and bulk populations could exponentially grow
after being propagated with a4-1BB (Figure 15). Prior to co-culture setup, autologous tumor
cells and CAPAN-1, a HLA-mismatched pancreatic tumor line for MP81, were stained for
MHCI expression (HLA-ABC) (Figure 16). Autologous tumor cells were found to express
low, but detectable levels of MHCI as compared to the CAPAN-1 cells (MFI: MP81 467,
MP64B 606 vs 5387 for CAPAN-1). In spite of this low level of MHCI expression, both IL2 grown and a4-1BB grown MP81 TIL secreted more IFN-γ in the presence of the
autologous target than with CAPAN-1 (Figure 14A). Upregulation of 4-1BB on CD8+ T cells
has been incorporated in tumor recognition assays previously [240, 250]. As such, both
MP81 TIL lines significantly upregulated 4-1BB expression after exposure to the tumor
target as compared to with the CAPAN-1 control Figure 14B and C). The upregulation of 4-
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1BB was particularly high on the CD56+ T-cell subset, a cytotoxic T-cell subset [251]. Given
that the 4-1BB expression was higher in the CD56+ CD8+ MP81 TIL subset, we assessed
MHCI-restricted recognition by blocking MHCI on its tumor target (Figure 14D and E, left
panels). It was observed that most of the recognition in the total CD8+ population was
MHCI-restricted for both culture conditions. This experimental setup was repeated with an
additional TIL and autologous tumor target (MP64B) with similar observations (Figure 14D
and E, right panels). Taken together, the IFN-γ secretion and elevated 4-1BB expression
indicate there are MHC class I-restricted tumor-reactive CD8+ T cells in the PDAC TIL
repertoire.
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Figure 14. Reactivity of PDAC TIL to an autologous tumor target.
(A-C) Sorted MP81 CD8+ TIL grown in IL-2+a4-1BB or IL-2 only were co-cultured for 24 h
with autologous tumor, HLA-mismatched tumor line CAPAN-1, or media (TIL only). All
conditions were in triplicate. (A) IFN-γ secretion was measured as well as (B, C)
upregulation of 4-1BB on CD56+CD8+ TIL. Part (B) shows the compiled results of dot plot
analysis of 4-1BB upregulation visualized by flow cytometry and (C) shows representative
dot plots of 4-1BB upregulation. Results for a4-1BB grown TIL and IL-2 only grown TIL are
from separate experiments. (D, E) Sorted MP81 CD8+ TIL (left graphs) and sorted MP64B
CD8+ TIL (right graphs) grown in IL-2+a4-1BB or IL-2 only were co-cultured for 24 h with
autologous tumor, pre-treated with MHC-I blocking antibody (W6/32) or isotype control
(IgG2a), or media (TIL only). All conditions were in duplicate or triplicate. Part (D) shows
the compiled results of dot plot analysis of 4-1BB upregulation visualized by flow cytometry
for MP81 CD8+ TIL (left graph) and MP64B CD8+ TIL (right graph). (E) shows
representative dot plots of 4-1BB upregulation.

Figure 15. Fold expansion of bulk and CD8+ PDAC TIL following the REP.
(A) Sorted PDAC CD8+ TIL (IL-2 alone or a4-1BB + IL-2) and (B) bulk a4-1BB stimulated
PDAC TIL were rapidly expanded and their fold expansion calculated on Day 14.
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Figure 16. Level of MHC class I expression on PDAC tumor cell lines.
HLA-A,B,C expression was assessed using flow cytometry on autologous PDAC tumor cell
lines as well as on a commercially available PDAC tumor cell line (CAPAN-1). Unstained
tumor cells were used as a control (red histogram). The mean fluorescence intensity (MFI) of
MHC class I expression for each line assessed is shown in the legend.

3.2.7: Further improvement of TIL culture process for PDAC with a 3-signal approach
As just shown above, the manipulation of 4-1BB through agonistic stimulation
(Urelumab, BMS), increased CD8+ TIL proliferation and improved culture success in
pancreatic cancer. Additional work to further improve the TIL culture method was performed
by our group which led to the development of a new methodology utilizing an anti-CD3
antibody (OKT3) in the early TIL culture as well as transitioning to TIL culture in a gaspermeable culture flask (GREX) to expand melanoma TIL [218]. The application of this
novel strategy, named TIL 3.0, to PDAC TIL culture led to the expansion of a greater
number of CD3+ TIL (200x106 average) compared to IL-2 only and IL-2+a41BB culture
methods (Figure 17A). This increase in CD3+ TIL number is characterized by a consistent
maintenance of the high percentage of CD8+ TIL (Figure 17B) and low percentage of CD4+
TIL (Figure 17C). The TIL 3.0 method also consistently reduced the time of culture from a
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period of 3-5 weeks for IL-2 only and IL-2+a41BB to 2-3 weeks (Figure 17D). Finally, TIL
3.0 drastically increased the overall success rate of establishing an PDAC TIL culture from
29% (10/34) for IL-2 only and 48% (16/33) for IL-2+a41BB to 95% (19/20) for the IL2+OKT3+a41BB method (Figure 17E). The benchmark for a successful TIL culture, 12x106
total cells, was established from scaling down the MDACC Clinical Melanoma TIL Lab’s
criterion for success where 20 fragments are set up for TIL expansion and 40x106 cells is
considered the minimum to treat a patient [252].

Figure 17. Characterization of PDAC TIL growth across culture conditions.
Comparison of the (A) total CD3+ TIL number, (B) percentage of CD3+CD8+ TIL, and (C)
percentage of CD3+CD4+ TIL generated between the different culture methods. Comparison
between culture methods of the (D) time of culture and (E) success rate of growth for all
attempted cultures.
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3.2.8 Synchronous stimulation of 4-1BB and CD3 prevents CD8+ TIL over differentiation
To understand how the different culture methods affected the CD8+ TIL, the
expression of CD28, BTLA, and PD-1 were explored as surrogates for T-cell activation and
differentiation (Figure 18). These 3 markers were strategically selected for the power of
assessment they provide individually as well as together. BTLA+CD8+ TIL have been
reported by our group to be less-differentiated cells, capable of prolong persistence and serial
killer capacities [188, 189]. Expression of CD28 is also a trait of lesser differentiation, while
the expression of PD1 is increased with chronic antigen exposure and exhaustion, thus
signifying later stage of differentiation [249, 253]. When comparing expression of the 3
markers on PDAC TIL expanded with IL-2 only or IL-2+a41BB, no significant difference
was observed. However, CD8+ TIL grown with the TIL 3.0 method were comprised of a
significantly greater percentage of cells expressing BTLA and CD28, and a significantly
smaller percentage of CD8+ TIL expressing PD-1, altogether suggesting a less differentiated
profile (Figure 18).
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Figure 18. Phenotyping of grown PDAC TIL across culture conditions.
Comparison between the different culture methods of the percentage of CD28, BTLA, and
PD-1 expressing CD8+ TIL generated.

3.3: Summary
In this chapter, it was shown that PDAC has a scarce, yet activated CD8+ TIL
infiltrate that is preferentially expanded with the addition of an agonistic 4-1BB mAb to the
TIL culture. The a4-1BB mAb consistently augmented total TIL numbers and doubled the
success rate of TIL growth without overly differentiating them in spite of the aggressive
proliferation spurred by 4-1BB costimulation. Finally, despite the fact that the a4-1BB mAb
favored expansion of distinct CD8+ T-cell clones from the tumor in comparison to IL-2
alone, TIL derived with either culture condition showed tumor recognition via IFN-γ
secretion and 4-1BB upregulation. While only two TIL lines and paired autologous tumor
targets were able to be tested, it was observed that there was a higher frequency of anti-tumor
reactive CD8+ TIL in the a4-1BB grown cultures compared with TIL grown in IL-2 alone.
Further improvements to the culture process by the addition of an agonistic 4-1BB mAb and
OKT3, a novel 3-signal approach, increased the ability to grow TIL from PDAC, improves
the total yield, and stimulates the proliferation of activated CD8+ T cells. Using the TIL 3.0
methodology to grow PDAC TIL brought about several major improvements; 1) reduce the
manufacturing time, 2) increase the success rate to over 90%, 3) require less tumor tissue
(only 5 tumor fragments, or the equivalent of 2 core needle biopsies). In the context of a
clinical trial, these improvements would make it possible to grow enough TIL to treat over
90% of the enrolled patients with a product consistently high in CD8 content. These results
suggest that the a4-1BB mAb can facilitate TIL ACT for PDAC by increasing the final yield
of the desirable, anti-tumor CD8+ T cells clones present in PDAC.
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Chapter 4: Heterogeneity of Pancreatic Cancer Tumor-Infiltrating Lymphocytes at the
Single-Cell Level
4.1: Introduction
While exploring the TCR repertoire in PDAC in the previous chapter, high frequency
T-cell clones overlapping between the tumor and uninvolved-tissue were observed,
potentially suggesting the presence of tissue-resident memory T cells (TRM). TRM are a unique
population of T cells that don’t recirculate between the tissue and periphery, and their
importance has only been elucidated within the past decade [254]. Instead, they are small
population of memory T cells that take up residence in peripheral tissues (e.g. skin, lungs, GI
tract) sites after trafficking there as a part of an immune response. By doing so, they can
function as a rapid response arm of the adaptive immune system to quickly engage any rechallenge. After pathogen clearance, signals in the local tissue environment, such as TGF-β
or IL-15, help promote a change in transcriptional programming that results in engraftment of
long-lived TRM population [255]. This TRM profile is typically characterized by upregulation
of genes associated with tissue retention (CD103, CD69, CD49a/ITGA1) and longevity (Bcl2, CD127/IL7Ra) coupled with downregulation of genes associated with tissue egress
(S1PR1/5, L-selectin/CD62L, CCR7, KLF2) [256].
The role of TRM was first appreciated in the context of infection as they were found to
mediate a novel mechanism of immunity that involved non-migratory T cells in barrier
tissues [257-259]. However, in recent years the importance of TRM in cancer immunity has
also been uncovered [260]. Several reports have demonstrated that the presence of TRM,
particularly CD103+CD8+ TRM, is correlated with improved survival in several epithelial
cancers [261-267]. The reason this correlation has been found predominantly in epithelial
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cancers is due to the fact that epithelial tissues express TGF-β, which induces CD103
expression on T cells, and the only known ligand for CD103 is the epithelial-associated
protein E-cadherin and is expressed on epithelial cells [260, 268]. The interaction between
CD103 on T cells and E-cadherin on tumor cells could play an important role in tumor
control as in vitro studies have shown that it is important for immune synapse formation and
subsequent release of cytolytic granules [269, 270]. Additionally, these TRM cells have also
been shown to harbor increased cytotoxicity, be composed of the tumor-reactive CD8+ TIL,
and have higher expression of checkpoint markers [261, 262, 264, 271-273]. In pancreatic
cancer, an in vitro study showed that CD103+CD8+ T cells more efficiently adhered to Ecadherin expressing tumor cells, thus allowing for increased cytolysis [274]. Given the
emerging importance of TRM in tumor control as reported in the literature as well as the hint
at their presence in our own study, we wanted to further explore TRM in PDAC.
To capture the breadth of the TRM phenotype in PDAC, we turned to multi-parameter
flow cytometry and single-cell RNA-sequencing (scRNAseq) for their ability to provide a
detailed understanding of diverse cell populations. scRNAseq in particular has emerged as a
powerful tool for immunological studies given the extreme heterogeneity of immune cells. T
cells are no exception to this, as their heterogeneity is governed by not only various
transcriptomic profiles that direct their development and differentiation, but also the diversity
of their TCRs. scRNAseq provides the means to asses a complex, and yet-to-be-fullydefined, cell population like TRM cells in an unbiased manner. Several studies have been
published in the last few years showing the power of scRNAseq to identify novel T-cell
phenotypes in different cancers [262, 275-280]. This approach is particularly attractive for
exploring TRM in PDAC due to the lack of a defined phenotype in this cancer type as well as
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PDAC’s overall low-level of immune infiltration. Therefore, we sought to explore the PDAC
TRM population by combining high-order flow cytometry, scRNA transcriptomic and TCR
sequencing.
4.2: Results
4.2.1 Exploring tissue-resident memory T cells in PDAC via CD103 expression
To initially determine the presence of TRM in PDAC, a subset of primary PDAC
samples (n=10) were analyzed using multi-parameter flow cytometry (Figure 19). In the
literature, the TRM population is typically characterized by expression of integrin αE (ITGAE,
also known as CD103), which is a well-characterized marker for TRM cells, as well
expression of several activation and checkpoint markers (CTLA4, PD-1, LAG3, TIM3 ICOS,
and Ki67). The majority of CD103 expression was found on CD8+ TIL with almost no
expression found on CD4+ TIL in freshly disaggregated primary tumor tissue (Figure 19A
and 19B). This is similar previously published data in OvCa showing that the CD103+ TRM
population is mainly within the CD8+ TIL compartment [266]. To better understand the
relative abundance of CD103 expression in PDAC, OvCa TIL were used as a point of
comparison due to the reported presence of CD103+ TRM in the literature (Figure 19C) [261].
Based on the percentage of CD103+ expression, PDAC was found to have about half as much
TRM on average as OvCa (21% vs. 45% respectively). The CD8+ TIL showed a large fraction
of PD-1+ and Ki67+ cells compared to the other markers (Figure 19A). To determine if these
markers were preferentially co-expressed with CD103, the differential expression between
CD103+ and CD103- CD8+ TIL was explored (Figure 19D). Compared to CD103-CD8+ TIL
(non-TRM), the CD8 TRM population showed only a trend for higher PD-1expression but
nothing statistically significant.
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Figure 19. Flow cytometry analysis of tissue-resident memory T cells in PDAC.
Expression of the TRM marker CD103 and several activation/inhibitory markers on (A) CD8+
TIL and (B) CD4+ TIL. (C) Comparison of the CD8+CD103+ TIL fraction in PDAC and
OvCa. (D) Comparison of activation and inhibitory markers on CD8+CD103+ or
CD8+CD103- TIL.
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4.2.2 Transcriptomic characterization of TIL isolated from primary pancreatic tumors
The lower proportion of of TRM based on CD103 expression in PDAC could be due to
the fact that it reportedly marks this T cell population mainly in barrier or mucosal tissues
(such as found in OvCa). Moreover, the literature indicates that TRM do not always express
CD103 [281]. This fact coupled with the self-limitation of flow cytometry panel using a
small number of selected markers prompted us to turn to an unbiased and more
comprehensive approach to elucidate the phenotype of TRM in PDAC. To interrogate this
phenotype in an unbiased manner, single-cell RNA sequencing was performed on 1,616
CD3+ TIL (922 CD8+ and 694 CD4+) freshly isolated from 6 primary PDAC samples (Figure
20). The patient characteristics for sequenced samples are presented in Table 3.

Figure 20. Schematic of sample processing for single-cell RNA sequencing.

79

Table 3. Patient characteristics for sequenced tumor samples.

After sample processing, the data was clustered unbiasedly using t-distributed
stochastic neighbor embedding (t-SNE) in collaboration with Aislyn Schalck in Dr. Nick
Navin’s lab (Figure 21 and 22). Four CD8+ TIL clusters (CD8_C1 EOMES, CD8_C2
ZNF683, CD8_C3 GZMB, and CD8_C4 STAT1) and 3 distinct CD4+ TIL clusters (CD4_C1
TCM, CD4_C2 Treg, and CD4_C3 TEM) were identified (Figure 21A and 22A). While 3/6 of
the samples provided the majority of the cells, the relative proportions of each cluster type
within each sample were similar to each other (Figures 21B and 22B). This indicated that the
clusters were comparable across the 6 samples.
When focusing on the CD8+ clusters, the CD8 TIL seems to be composed of several
activated or cytotoxic populations based on expression of several markers (Figure 21C).
CD8_C1 has expression of several MHC Class II alleles plus GZMK, which are markers of T
cell activation. CD8_C2 has high expression of CD69, a well-known activation marker.
CD8_C3 appears to be a cytotoxic effector cell population based on expression of GZMB,
GNLY, PRF1, and NKG7. Finally, CD8_C4 has high expression of Type I interferon (IFN-I)
response genes (IFIT1, IFIT3, IRF7, STAT1), suggesting exposure to IFN-1 which has been
shown directly and indirectly promote activation and proliferation of CD8+ T cells. As
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hypothesized, based on the low CD103 expression found by flow cytometry, no TRM cluster
defined by CD103 appeared within the CD8 population. Instead, we found a potential TRM
cluster that was defined by expression of ZNF683 and CD69 (Figure 21C). While CD69 is
primarily thought of as a marker of activation, it has also been found to mark TRM T cells.
More importantly, however, is the expression of the transcription factor ZNF683 (also known
as Hobit, or homolog of Blimp-1 in T cells) which is reported to be important for TRM
formation. Furthermore, high expression of CD69 and ZNF683 was coupled with low
expression of KLF2, S1PR5, and ZEB2 (Figure 21C). This expression profile is similar to
that described for TRM cells in the literature [255, 278, 282]. Finally, expression of
checkpoint molecules PD-1 or TIM3 were not associated with the TRM, which is in contrast to
published observations from other cancer types.
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Figure 21. Characteristics of CD8+ TIL populations in primary PDAC
(A) t-SNE plot of 922 CD8+ TIL colored by patient and demarcated by colored circles
indicating four distinct clusters based on gene expression differences. (B) Bar graphs
showing the cell number contributed by each sample to a cluster (left) and its relative
proportion (right) (C) Heatmap from single-cell RNAseq unsupervised clustering analysis
defines 4 clusters as indicated by colored bars along the x-axis. Figure generated in
collaboration with Aislyn Schalck and Dr. Nick Navin and used with their permission.

Within the CD4 population, CD4_C1 surprisingly had expression of CCR7 and TCF7
which are indicative of a central memory T cell population (Figure 22C). Given that TCM are
not frequently found at tumor sites, this population is likely contamination from circulating
CD4 T cells in the blood that may have been passing through the tumor. While Tregs were
not detected at a high level by flow cytometry (Figure 19B), the CD4_C2 population appears
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to be a robust and activated Treg population based on expression of the classical Treg
markers FOXP3 and CD25 as well as the activation markers GITR, OX40, TIGIT, CD39, and
4-1BB. Interestingly, the Treg population also had high expression of IL-32, typically known
as a pro-inflammatory cytokine. Finally, CD4_C3 contained an activated Th1 CD4 subset as
evidenced by expression of CD40LG, CD69, and IL-2 (Figure 22C). In addition, the cells
from this cluster may harbor some effector cell functions based on expression of granzyme A
and K.

Figure 22. Unsupervised clustering of CD4+ single cell transcriptomes.
(A) t-SNE plot of 694 CD4+ TIL colored by patient and demarcated by colored circles
indicating three distinct clusters based on gene expression differences. (B) Bar graphs
showing the cell number contributed by each sample for each cluster (left) and its relative
proportion (right) (C) Heatmap from single-cell RNAseq unsupervised clustering analysis
reveals 3 clusters as indicated by colored bars along the x-axis. Figure generated in
collaboration with Aislyn Schalck and Dr. Nick Navin and used with their permission.
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4.2.3 Characterization of TIL clonal repertoire in the tissue
In addition to transcriptomic sequencing of the TIL, single-cell TCR sequencing was
performed in order to compare the frequency of clonal populations with the transcriptomic
profile they have. Enrichment of a certain clonal population at a tumor site in indicative of
that population participating in an immune response. To that end, Circos plots were
generated for the CD8 and CD4+ TIL separately (Figure 23 and 24). The inner ring is colorcoded by sample, the next ring is color-coded by transcriptomic cluster, and the grey outer
ring contains bars that indicate the relative frequency of that TCR clone. The CD8+ TIL
Circo indicates that the clones that are enriched at the tumor site (found in numerous copies,
delineated by the tall grey bars on the outer circle) mainly come from clusters CD8_C1
EOMES and CD8_C2 ZNF683, while the other two clusters show little to no enrichment of
clones within them (Figure 23). On the other hand, the CD4+ TIL Circo plot shows little
clonal expansion of clones overall (Figure 24). Of the clones that show some measure of
expansion, the majority are in the CD4_C2 Treg cluster followed by a few in the CD4_C3
TEM cluster. While only one or two samples seem to have most of the clonal CD8 expansion
detected, the CD4 clonal expansion appears to be spread more evenly among the samples.
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Figure 23. CD8+ TIL Circos plot combining transcriptomic profile with TCR frequency.
The inner ring is color-coded by sample, the next ring is color-coded by transcriptomic
cluster, and the outer ring contains bars that indicate the relative frequency of that TCR
clone. Figure generated in collaboration with Aislyn Schalck and Dr. Nick Navin and used
with their permission.
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Figure 24. CD4+ TIL Circos plot combining transcriptomic profile with TCR frequency.
The inner ring is color-coded by sample, the next ring is color-coded by transcriptomic
cluster, and the outer ring contains bars that indicate the relative frequency of that TCR
clone. Figure generated in collaboration with Aislyn Schalck and Dr. Nick Navin and used
with their permission.
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4.2.4 TIL 3.0 produces a large proportion of cytotoxic and proliferative CD8+ TIL
To better understand the effect of the TIL 3.0 culture method on the TIL generated,
expanded TIL products from the same tissues that were initially sequenced were also sent for
transcriptomic and TCR scRNAseq (MP108, MP109, MP112, MP115, MP116, and MP121;
Figure 25A). Initial tSNE anlaysis revealed 7 populations, which were classified based on
unsupervised heatmap clustering: C1_CD4-OX40, C2_CD8-GZMB, C3_CD3-CYCLING,
C4_CD3-DYING, C5_γδ-TCELL, C6_CD4-MHCII, and C7_CD8-HSP (Figure 25B and
25C). Based on the tSNE clustering, the major populations present were a cytotoxic CD8
cluster (CD8_GZMB) defined by expression of GZMB and PRF1, and a proliferative T cell
population (CD3_CYCLING) defined by expression of cell-cycle related genes like KI67,
TUBB, and TOP2A (Figure 25C). Furthermore, it is apparent that the proliferating cell
population is mainly coming from the cytotoxic CD8 cluster based on proximity and shape of
the CD8-GZMB and CD3-CYCLING clusters (Figure 25B). The fact that these are the two
main populations meshes well with the previous observation that TIL 3.0 produces a large
TIL product that consists mainly of activated CD8+ TIL (Figure 17 and 18). In addition to the
major activated CD8-GZMB cluster, a smaller CD8 cluster (C7_CD8-HSP) was found that is
curiously characterized by expression of several heat-shock proteins (HSPs) which are
chaperone proteins known for promoting cell survival under stress conditions.
While the majority of TIL produced by TIL 3.0 are CD8+ T cells, there were also two
small clusters of activated of CD4+ TIL (C1_CD4-OX40 and C6_CD4-MHCII) as well as a
γδ T cell cluster (C5_γδ-TCELL) (Figure 25B). The larger of the CD4 clusters (C1_CD4)
had, surprisingly, an activated phenotype as defined by expression of CD40LG, TNFRSF4
(OX40), and TNFRSF18 (GITR) (Figure 25C). The minor CD4 cluster (C6_CD4) was
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defined by high expression of several MHCII alleles as well as expression of IL5 and IL13.
Since γδ T cells can be stimulated by a41BB, a small component of these TIL were detected
in the TIL products. This γδ T cell cluster, C5_γδ-TCELL, was defined chiefly by expression
of TRDC (γδ TCR) but also had expression of genes associated with activation like GNLY,
CCL3 (MIP1a), XCL1, and XCL2. Finally, a cluster of cells was detected (C4_CD3-DYING)
that had increased expression of mitochondrial genes, which indicates they are likely
undergoing apoptosis.

Figure 25. Transcriptomic scRNAseq of grown PDAC TIL.
(A) Tissue from the same samples that were sent for scRNAseq of fresh TIL were used to
generate a TIL product using the TIL 3.0 protocol. tSNE clustering (B) and unsupervised
clustering (C) were generated from the transcriptomic data, revealing 7 transcriptomic
clusters. Figure generated in collaboration with Aislyn Schalck and Dr. Nick Navin and used
with their permission.
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4.2.5 TIL 3.0 maintains high frequency clones from activated TIL populations
Previous work presented in Chapter 3 Section 3.2.5 looked at the frequency of clones
in the fresh tumor in comparison to their frequency in the TIL product after culture with IL2+a41BB. This TCR sequencing analysis revealed that high frequency clonotypes in the
tissue did not necessarily expand to a proportionally high frequency in the in the TIL product
and vice versa. To explore how this relationship might change with TIL 3.0, which now
includes an additional stimulation with OKT3, the frequency of clonotypes in the fresh tumor
(Fresh TIL, black) and TIL product (Grown TIL, blue) were compared (Figure 26). Analysis
of sequencing data found TIL 3.0 is able to maintain the original frequency of clones found
in the tumor tissue. In other words, if a clonotype was at a high frequency in the tissue it was
also a high proportion of the grown TIL.
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Figure 26. Preservation in the TIL product of the initial clonal dominance in fresh
tissue.
Six TIL products were TCR scRNAseq’d and the relative frequency of their clonotype
repertoire was compared to that found in the tissue. The clonotypes from the fresh TIL are in
black and the grown TIL are in blue. The number of clonotypes in each increases up the yaxis. Along the x-axis, starting in the middle at 0 in either direction, the relative frequency in
the grown TIL (blue) or fresh TIL (black) increases. The number of clonotypes detected in
the grown TIL product for each sample is also shown. Figure generated in collaboration with
Aislyn Schalck and Dr. Nick Navin and used with their permission.

The process of TIL expansion alters the transcriptome of TIL. To track TIL
transcriptomic features through expansion, we made use of the TCR sequence information to
link transcriptomes pre and post expansion (Figure 27). Figure 27A represents the expanded
clones, mapped to their initial cluster in the fresh tissue (Figure 27B), where solid circles
represent clones that expanded and shaded circles represent clones that did not expand (i.e.,
were not found in expanded TIL). The CD8 clusters in the tSNE plot are color coded to
correspond with the phenotypic groups in the heatmap. Expanded clones were found to come
from all four phenotypic clusters that were identified, particularly the CD8-EOMES and
CD8-ZNF683 clusters (Figure 27A). In Figure 27A and 27B, the same tSNE clustering and
heatmap are shown as in Figure 21C.
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Figure 27. Comparison of the phenotypic profile from which the grown TIL were
generated.
(A) tSNE clustering of fresh CD8 TIL, where closed circles indicate the clone was detected
in the grown TIL product and open circle indicates it was not detected. The clusters are also
color coded to match the phenotypic profiles displayed in (B) the heat map. Figure generated
in collaboration with Aislyn Schalck and Dr. Nick Navin and used with their permission.

4.3: Summary
In summary, initial flow cytometry on several fresh, primary PDAC samples data did
not detect a substantial tissue-resident memory T cell population as classically defined by
having expression of CD103 and checkpoint markers. However, single-cell RNA
transcriptomic sequencing allowed for unbiased analysis of the TIL heterogeneity in these
samples. Transcriptomic sequencing revealed 4 distinct CD8+ TIL clusters and 3 distinct
CD4+ TIL clusters. While there is variability in the TIL infiltration, the relative proportion of
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these clusters is similar across patients. Additionally, scRNAseq was able to identify cell
populations that were not appreciated by flow cytometry, such as a CD69+ZNF683+ TIL
population that may represent the true phenotype of TRM-like CD8+ T cells found in PDAC as
compared to the classically-defined phenotype with CD103. Furthermore, sequencing
revealed a highly activated Treg population that would have otherwise been overlooked if the
analysis was based solely on flow cytometry data.

Finally, paired single-cell TCR

sequencing revealed that, although there was not a substantial amount of clonal TIL
expansion, the majority of this expansion belonged the potentially important CD8+ TRM and
the CD4+ Treg populations. Using this paired TCR-transcriptome sequencing data to analyze
the TIL grown with TIL 3.0 showed the major populations that compose the TIL product are
an activated and cytotoxic CD8 population that is proliferating. Additionally, the TCR
sequencing data shows that, notably, TIL 3.0 is able to expand CD8+ TIL from the high
frequency and activated clonotypes. Overall, this analysis shows the potential of combining
multi-parameter flow cytometry and scRNAseq in defining the heterogeneity of TIL in
PDAC.
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Chapter 5: Potential clinical application of tumor-infiltrating lymphocyte therapy for
ovarian epithelial cancer prior or post-resistance to chemotherapy
This chapter is based on the original research article “Potential clinical application of tumorinfiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to
chemotherapy” published by Sakellariou-Thompson et al. in Cancer Immunology,
Immunotherapy on October 10th, 2019 (DOI: 10.1007/s00262-019-02402-z). It is presented
with permission from Springer as per sections 4a and 4c of the “Authors’ Retained Rights”
section of the Copyright Transfer Statement document which states, in part:
“Author(s) retain the following non-exclusive rights for the published version
that, when reproducing the Article or extracts from it, the Author(s)
acknowledge and reference first publication in the Journal:
(a) to reuse graphic elements created by the Author(s) and contained in the
Article, in presentations and other works created by them;
(c) to reproduce, or to allow, a third party Assignee to reproduce the Article
in whole or in party in any printed volume (book or thesis) written by the
Author(s).”
5.1: Introduction
Epithelial ovarian cancer (OvCa) is the deadliest gynecological cancer, and is
estimated to account for almost 14,000 deaths in 2018 [283]. Although prognosis of earlystage OvCa is favorable, 70% of patients are diagnosed with advanced and metastatic
disease [284]. Traditional management of advanced stage OvCa includes tumor reductive
surgery and adjuvant platinum-taxane chemotherapy, which results in high rates of initial
complete response. However, nearly 90% of patients recur and the 5-year survival rate for
late-stage disease is only 28% [285, 286].
Nevertheless, OvCa possesses a strong immune infiltrate that could provide an
avenue to greater treatment efficacy and better long-term survival in the context of
immunotherapy. Several groups have shown that the presence of CD8+ TIL is associated with
a greater 5-year survival in OvCa, suggesting that CD8+ TIL exert some degree of tumor
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control [85, 216, 287-291]. This provides a rationale for the use of immunotherapy to harness
the anti-tumor potential of this immune infiltrate. Checkpoint blockade immunotherapy has
already made a tremendous mark in the treatment of cancer. Its success was first observed in
the treatment of metastatic melanoma with agents that block the CTLA-4 and PD-1 axis [43,
226, 227, 292, 293]. This approach was later transposed to non-small cell lung cancer and
renal cell carcinoma [228-230]. Unfortunately, the success of checkpoint blockade has not
been reproduced in OvCa to date [210, 294, 295].
Since in vivo manipulation of the TIL through checkpoint blockade does not seem to
be sufficient to generate a strong clinical response, approaches involving ex vivo
manipulation of immune cells, such as adoptive cell therapy (ACT) using autologous TIL,
might be able to provide a large quantity of anti-tumor T cells needed for tumor control. Our
group and others have demonstrated the effectiveness of TIL ACT in metastatic melanoma
[94, 95, 108, 237]. With objective response rates (ORR) of 40-50% in metastatic melanoma,
TIL ACT is among the best treatment options for this patient population. In the 1990s,
several groups attempted to transpose TIL ACT to OvCa either alone or in combination with
chemotherapy, or in the adjuvant setting after debulking surgery [296-300]. These early trials
had some promising results but suffered from a few limitations. Later studies demonstrated
the need for lymphodepleting pre-conditioning regimens for long term TIL engraftment and
improved cell generation methodologies that resulted in the infusion of patients with greater
cell numbers [301]. Furthermore, improvements in techniques for TIL enrichment and
activation, mainly for CD8+ TIL as they have been correlated with clinical response in
melanoma, may increase favorable clinical outcomes in OvCa TIL trials [95, 108].

94

As stated previously, the manipulation of 4-1BB/CD137 through agonistic
stimulation (Urelumab, BMS), increased CD8+ TIL proliferation in melanoma, triple
negative breast cancer and pancreatic cancer [220, 243, 252]. Additional work to further
improve the culture method was also done by adding an anti-CD3 antibody (OKT3) to the
early TIL culture as well as transitioning to TIL culture in a gas-permeable culture flask
[218]. Here, the addition of an agonistic 4-1BB mAb and OKT3, a novel 3-signal approach,
increases the ability to grow TIL from OvCa, improves the total yield, and stimulates the
proliferation of activated CD8+ T cells. In addition, these CD8+ TIL displayed HLArestricted tumor recognition. These results support the use of TIL expanded with a41BB and
OKT3 in ACT strategies for patients with OvCa.

5.2 Results for OvCa TIL
5.2.1 Primary and metastatic OvCa TIL infiltrate is predominantly CD8+ T-cell rich
The lymphoid immune infiltrate was assessed at the onset of the culture by
performing flow cytometry on manually disaggregated primary and metastatic tumor samples
(n=84). The proportion of CD3+ TIL among live cells recovered varied widely among
samples (median 3%, range 0.1%-20%) (Figure 28A). Infiltration by NK cells was overall
less (median 1% range 0.1%-35%) (Figure 28A). However, CD3+ TIL were a significantly
greater portion of the infiltrate than NK cells in most cases (p<0.0001).
Because TIL ACT for OvCa would most likely target patients who progressed on
standard of care and thus would be administered to chemo-refractory patients likely to be
metastatic, the contribution of those parameters on the T-cell infiltration was investigated.
When patients were stratified by chemotherapy exposure and surgery site, metastatic tumors
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were found to have more CD3+ TIL than primary tumors (median 4% vs. 1.5%, p=0.029) as a
component of live cells (Figure 28B). No significant difference in the proportion of CD3+
TIL was found between pre-chemotherapy and post-chemotherapy samples (Figure 28C).
Within the CD3+ TIL compartment, the mean CD8:CD4 ratio was 1.5 demonstrating
that OvCa is predominately infiltrated by CD8+ TIL (Figure 28D). No difference in the
CD8:CD4 ratio was found in the context of primary/metastasis and pre/post-chemotherapy
(Figure 28E and 28F). As a point of comparison, both the CD3+ TIL infiltration and
CD8:CD4 ratio were found to be similar to what our group has previously reported in
metastatic melanoma [252], suggesting that OvCa tumors are relatively well infiltrated by T
cells.
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Figure 28. Characterization of lymphocyte infiltrate in primary/metastatic and
pre/post-chemo OvCa samples.
(A) T cell (CD3+) and NK cell (CD3-CD56+) infiltration is compared within the live
lymphocyte population using flow cytometry, with the horizontal bar representing the median
value of each population (n=84). T cell (CD3+) infiltration is compared between (B) primary
and metastatic sites, and (C) pre- and post-chemo samples, with the horizontal bars
indicating the median value (n=84). (D) The ratio of CD8+% to CD4+% T cells within the
CD3+ compartment is displayed. The dotted line indicates where a ratio of 1 is in relation to
the average ratio which is represented by the solid horizontal line (n=72). The CD8/CD4
ratio is compared between (E) primary and metastatic sites and (F) pre- and post-chemo
samples, with the horizontal bars indicating the median value (n=72). Samples that had less
than 100 cells within the CD8 and CD4 gates were excluded from analysis.

5.2.2 Use of agonistic 4-1BB mAb and anti-CD3 increases TIL growth and success rate
Prior work by our group detailed how infusion of melanoma patients with a higher
proportion of CD8+ T cells and larger amount of TIL in general correlates with clinical
response [95, 108]. It was reasoned that CD8+ TIL could also be important in other solid
tumor types as their presence correlates with improved survival. Thus, the two new
methodologies, which aimed at facilitating the expansion of CD8+ TIL from ovarian cancer
tissue, were tested next (Figure 29).
Fresh tumor samples were set up for TIL culture using the different expansion
methods. The first method compared IL-2 only versus IL-2 plus an agonistic 4-1BB mAb
(a41BB). Use of a41BB significantly increased the average total CD3+ TIL growth from
30x106 cells for IL-2 alone to 50x106 for IL-2 + a41BB (Figure 29A). Additionally, a41BB
greatly increased the average percentage of CD8+ TIL in culture from 30% for IL-2 alone to
65% for IL-2 + a41BB (Figure 29B). A corresponding decrease in the average percentage of
CD4+ TIL from the IL-2 only condition to the IL-2 + a41BB condition was also observed
(Figure 30). The mean CD4+ percentage dropped from 50% to 5% (Figure 30A) and the
median CD8-to-CD4 ratio increased from 0.4 to 60 respectively (Figure 30B).
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Figure 29. Characterization of OvCa TIL growth across culture conditions.
Comparison of the (A) total CD3+ TIL number, (B) percentage of CD3+CD8+ TIL, and (C)
percentage of NK cells generated between the different culture methods. Samples in IL-2 and
IL-2+a41BB conditions are paired (n=30) while samples in IL-2+OKT3+a41BB are unpaired
(n=36). For (A), (B), and (C), only samples that grew are shown. Some samples are not
shown due to dropout after QC. The horizontal bars indicate the mean value and SD are
shown for each population. Comparison between culture methods of the (E) time of culture
and (E) success rate of growth for all attempted cultures. In E, IL-2+a41BB has 55 samples
because one sample was set up without an IL-2 only counterpart culture.
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Figure 30. Characterization of OvCa CD4+ TIL growth.
Comparison between the different culture conditions of (A) percentage of CD4+ TIL and (B)
the %CD8+/%CD4+ ratio from successful cultures. For (A), The horizontal bars indicate the
mean value and SD, and in (B) the horizontal bars indicate the median value.

However, since NK cells can also express 4-1BB, the addition of the a41BB mAb
increased their growth as well from 15% to 40% of the expanded culture on average (Figure
29C). To avoid expansion of NK cells, a 3rd culture strategy using an agonistic stimulation of
CD3 with an anti-CD3 mAb (OKT3) was implemented. Similar to previous work for
metastatic melanoma TIL expansion, this strategy (named TIL 3.0) led to a high percentage
of CD8+ TIL (80% average, Figure 29B) with a low percentage of CD4+ TIL (10% average,
Figure 30), and NK cells (5% average, Figure 29C) [218]. Protocol-induced changes in CD4+
Tregs were not assessed due to prior observations that high-dose IL-2 does not allow Treg
growth and abrogates their function [243, 302]. To show the benefit of a41BB, a sub-set of
10 samples were cultured with IL-2 + OKT3 (no a41BB) and compared with TIL 3.0 (Figure
31). Without a41BB, the total number of CD3+ TIL and the percentage of that which were
CD8+ TIL were both diminished while NK cells remained low (Figure 31A).
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TIL 3.0 also produced a greater number of OvCa TIL (mean of 200x106 cells) after a
period of 2-3 weeks, as opposed to the 3-5 weeks required for the other two methods (Figure
29A and 29D). The consistent reduction in culture time was lost when IL-2 + OKT3 without
a41BB was used and the yield of TIL was inferior (Figure 31B). The time of expansion did
not appear to depend on chemotherapy exposure (Figure 32A), although CD3+ TIL from
post-chemotherapy samples grew slightly, but significantly, less (225x106 vs. 200x106,
p=0.028) using TIL 3.0 (Figure 32B). Regardless, all TIL 3.0 cultures produced markedly
more TIL than IL-2 only or IL-2+a41BB.

Figure 31. Characterization of OvCa TIL growth using IL-2+OKT3 without a41BB.
Comparison of (A) total CD3+ TIL number, percentage of NK cells, percentage of
CD3+CD8+ TIL, and CD3+CD4+ TIL between IL-2+OKT3 and TIL 3.0. Only samples where
both conditions produced TIL are shown (n=8). The horizontal bars indicate the mean value
and SD is shown for each population. Comparison of the (B) time of culture and success rate
between culture methods (n=10 for both).
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Figure 32. Chemotherapy exposure does not affect OvCa TIL growth.
Comparison of (A) the days in culture, (B) total CD3+ TIL growth, and (C) growth success
rate for all three conditions between pre- and post-chemotherapy samples. (A) and (C) show
all attempted cultures and (B) shows only cultures that grew. In (B), the horizontal bars
indicate the mean value and SD are shown for each population.

The overall success rate of establishing an OvCa TIL culture was greatly increased
from 41% (22/54) for IL-2 only and 76% (42/55) for IL-2+a41BB to 95% (41/43) for the IL2+OKT3+a41BB method (Figure 29E). The benchmark for a successful TIL culture, 12x106
total cells, was established from scaling down the MDACC Clinical Melanoma TIL Lab’s
criterion for success where 20 fragments are set up for TIL expansion and 40x106 cells is
considered the minimum to treat a patient [252]. Chemotherapy exposure only affected the
success rate of expansion for the IL-2 only condition, with the success being 45% (13/29) for
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pre-chemotherapy and 36% (9/25) for post-chemotherapy (Figure 32C). This discrepancy
was negated for the IL-2+a41BB and TIL 3.0 methods.
It was assessed if the presence of TIL in the fresh sample affected the success of
growth (Figure 33). When comparing the percentage of CD3+ TIL in the fresh sample vs the
number grown, there was a strong correlation (rS > 0.5) for the IL-2 only culture method
where more CD3+ TIL grew if there were a higher percentage of CD3+ TIL present in the
initial tumor tissue (Figure 33A). Moreover, it was apparent that cultures with less than 2%
CD3+ TIL in the initial tumor tissue cultured with IL-2 alone did not grow, but cultures
initiated with as little as 0.2% CD3+ T-cell infiltrate could yield appreciable number of TIL
when cultured with IL-2+OKT3+a41BB. However, while the IL-2+a41BB and TIL 3.0
culture conditions did not show as strong of a correlation with T-cell infiltration (rS < 0.5),
the overall trend was the same as indicated by the positive slopes of the linear regression
lines (Figure 33A). There was no strong correlation with respect to the CD8+/CD4+ ratio of
fresh TIL and the amount of CD8+ TIL generated, particularly for the IL-2 only condition
due to the lack of CD8+ TIL generated by this method (Figure 33B). Overall, there was a
positive trend towards growing more CD8+ TIL if there was a higher CD8+/CD4+ ratio
initially as indicated by the slopes of the regression line for IL-2+a41BB and IL2+OKT3+a41BB.
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Figure 33. Correlation between amount of OvCa TIL present in fresh tissue and
magnitude of TIL growth.
(A) Comparison between %CD3+ TIL (in live cell population) in fresh sample versus the
total CD3+ TIL grown for IL-2 only (red), IL-2+a41BB (blue), and TIL 3.0 (black). The
dashed vertical line indicates the cutoff at which IL-2 cultures don’t grow if initial CD3% is
<2%. (B) Comparison between %CD8/%CD4 ratio in fresh sample versus the total CD8+ TIL
grown for each condition. Each sample is paired between the fresh sample and the TIL
number generated from the same sample. rS = Spearman correlation coefficient, p value is for
the significance of the correlation, m = slope of the linear regression line (solid lines that
represent general trend of the population).
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5.2.3 Concurrent engagement of 4-1BB and CD3 prevents CD8+ TIL over differentiation
To understand how the different culture methods affected the CD8+ TIL, the
expression of CD28, BTLA, and PD-1 expression were explored as surrogates for T-cell
activation and differentiation (Figure 34). These 3 markers were strategically selected for the
power of assessment they provide individually as well as together. BTLA+CD8+ TIL have
been reported by our group to be less-differentiated cells, capable of prolong persistence and
serial killer capacities [188, 189]. Expression of CD28 is also a trait of lesser differentiation,
while PD1 is often associated with exhaustion when highly expressed [249, 253]. When
looking at expression of the 3 markers on OvCa TIL expanded with IL-2 only and IL2+a41BB, no significant difference was observed between both groups. Nonetheless, both
showed a spread in CD28 and PD1 expression (Figure 34, left and right graph) with a low
expression of BTLA (Figure 34, middle graph). However, TIL products grown with the TIL
3.0 method had significantly greater percentage of TIL expressing BTLA and CD28, and a
significantly smaller percentage expressing PD-1 altogether suggesting a less differentiated
profile (Figure 34).
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Figure 34. Phenotyping of activation and differentiation of grown OvCa TIL.
Comparison between the different culture methods of the percentage of CD28, BTLA, and
PD-1 expressing CD8+ TIL generated. Samples in IL-2 and IL-2+a41BB conditions are
paired (n=28) while samples in IL-2+OKT3+a41BB are unpaired (n=25). Samples not
passing QC were excluded from analysis. The horizontal bars indicate the mean value and
SD are shown for each population.

5.2.4 OvCa CD8+ TIL show HLA-matched tumor reactivity
In order for TIL ACT to be an effective therapy, the TIL generation process needs to
expand anti-tumor T cells. Since the three different growth methods used could potentially
change the expanded TIL repertoire, tumor reactivity was used as a marker to validate
preservation of tumor-reactive TIL clones. Since our main focus is reactivity of cytotoxic
CD8+ T cells, each TIL line was sorted for CD8+ TIL and further expanded using the rapid
expansion protocol to achieve sufficient cell numbers. Eight TIL lines were chosen to assess
HLA-matched tumor reactivity that were representative of the different culture methods,
surgery sites, and prior chemotherapy exposure, which is summarized in Table 4.
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Table 4. Tumor targets for each TIL line and the HLA alleles for which they match.

For the first set of four lines, reactivity was assessed comparing initial growth with
IL-2 only or IL-2+a41BB (Figure 35A). The second set of four lines had reactivity compared
between those expanded with IL-2+a41BB or with TIL 3.0 (Figure 35B). Prior to co-culture
setup, all tumor lines were found to express robust levels of HLA class I by flow cytometry
(SKOV3, MFI: 2962; COV318, MFI: 5343; COV362, MFI: 2182; Figure 36). As shown in
Figure 35A, upon co-culture of the CD8+ TIL with tumor targets, 2/4 of the first set (15-094
and 16-025B) demonstrated HLA-restricted anti-tumor reactivity via secretion of IFN-γ. The
reactivity was split between one line grown with IL-2+a41BB (15-094) and one with IL-2
only (16-025B). Likewise, in Figure 35B, 3/4 of the second set of TIL lines were reactive
against their HLA-matched target. One TIL line (18-121) even recognized two different
tumor lines. Two TIL lines in this group (17-309 and 18-121) showed reactivity regardless of
culture method while one showed reactivity only from TIL grown with IL-2+a41BB (17378). Overall, TIL recognition of HLA-matched tumor targets was observed across the
multiple expansion platforms.
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Figure 35. Testing reactivity of CD8+ OvCa TIL via IFN-γ ELISPOT.
(A) Comparison of reactivity of TIL grown with either IL-2 only (red) or IL-2+a41BB (blue)
for four different lines, with a representative ELISPOT image shown. (B) Comparison of
reactivity of TIL grown with either IL-2+a41BB (blue) or IL-2+OKT3+a41BB (white) for
four different lines, with a representative ELISPOT image shown. Bar graphs show average
of 3 replicate wells with the SD and average spot value for each condition above the bars.
Reactivity was considered positive if the average was ≥ twice the xMHC condition. xMHC =
MHCI block, Iso = isotype control for MHCI blocking Ab, TIL only = T cells with media
only, PMA/Iono = PMA and Ionomycin for positive control, TNTC = too numerous to count.

Figure 36. HLA-ABC expression of OvCa cell lines.
The expression of MHCI alleles A, B, and C is shown in comparison to an unstained control.
The mean fluorescence intensity (MFI) is shown in the legend to indicate the magnitude of
expression.
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5.3 Summary for OvCa TIL
It was observed that OvCa has a robust and activated CD8+ TIL infiltrate that is not
significantly impacted by surgery site or resistance to chemotherapy. This infiltrate is greatly
expanded with the addition of an agonistic 4-1BB mAb to the TIL culture. Furthermore,
specific growth of CD3+CD8+ TIL is augmented by adding the anti-CD3 Ab OKT3. The 41BB mAb alone and together with OKT3 consistently improved the success rate of reaching
a clinically relevant number of TIL. Finally, OvCa CD8+ TIL derived with either culture
method showed tumor recognition via IFN-γ secretion in response to HLA-matched ovarian
cancer cell lines. These results suggest that enhanced culture method can facilitate TIL ACT
for OvCa by increasing the yield of a TIL product containing anti-tumor CD8+ T cells
regardless of primary or metastatic site, and in a chemotherapy refractory setting.
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Chapter 6: Discussion
Immunotherapy has drastically remodeled the landscape of cancer therapy by
harnessing the power of our own immune system. The most prominent example of this is the
development of checkpoint blockade therapy, which inhibits immune regulatory checkpoints
in order to reinvigorate anti-tumor T cell activity. This concept has delivered great
improvements in terms of response rates and survival to several solid tumor types such as
advanced melanoma, non-small cell lung cancer, renal cell carcinoma, and all MSI-high
cancers. While much success has been found for these cancer types, which are often highly
immunogenic [206-208], there are many others (e.g. pancreatic, ovarian, breast, MSS
colorectal, prostate cancers) which have not yet derived benefit even though they are in great
need of improved therapy options. Given the heterogeneity of cancers, the immune
contexture of some tumor types may not be conducive to CBI which relies on in vivo
manipulation of the immune response. Therefore, certain tumors may benefit most from an
immunotherapy that approach the issue from another angle such as TIL-based ACT.
TIL ACT can take advantage of antigen-specific TIL by expanding them ex vivo in an
environment conducive to their activation and proliferation. TIL ACT has already found
success in metastatic cutaneous melanoma where it provides overall response rates around
40-50% [94, 95, 109, 152, 238]. Despite the lack of efficacy of CBI for several of these
cancer types (pancreatic, ovarian, breast, MSS colorectal, prostate), there is still evidence for
the role TIL in control of these tumors [27]. Therefore, the success of TIL ACT in melanoma
could be translated to other tumor types. As such, in this dissertation, I sought to assess the
feasibility of this therapy in other solid tumors that still have an unmet need. Specifically, I
was guided by the hypothesis that tumor-specific TIL exist in solid tumors beyond melanoma
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and their potential for tumor clearance can be harnessed through TIL ACT. In order to
address this question, pancreatic ductal adenocarcinoma (PDAC) and high-grade serous
ovarian cancer (OvCa) were chosen as models. Both PDAC and OvCa are often diagnosed at
a late stage and face poor prognoses with 5 year survival rates of <10% and 28%
respectively. CBI has failed to provide improved clinical benefit for either [209-211, 294,
295]. Therefore, patients still rely on surgery and/or chemotherapy as treatment options, but
the majority recur due to the limited effectiveness. Despite the lack of efficacy for CBI so far
in PDAC and OvCa, the presence of T cells in the tumor tissue (TIL) is correlated with
increased survival in both [85, 216, 290, 291]. Therefore, over the course of investigating
transposing TIL ACT to PDAC and OvCa, I determined that both harbored tumor-reactive
CD8+ TIL that could be expanded ex vivo for the potential application of TIL ACT. I also had
the opportunity to improve the TIL expansion to increase the feasibility for PDAC and OvCa
by using the three core signals needed to proper T-cell expansion and activation. Finally, I
was able to use single-cell RNA sequencing to deeply interrogate the heterogeneity of PDAC
TIL in an unbiased manner. This analysis revealed a potentially prognostically relevant TIL
population as well as showing that the improved culture process expanded the highfrequency and activated T cell clones. In this chapter, these results will be discussed within
the greater context of the field as well as potential future directions.
Understanding the TIL compartment of a tumor type is key to assessing the feasibility
of TIL ACT as success is likely to rely, in part, on the quantity and quality of TIL present.
Flow cytometry analysis provided insight into the general makeup of the TIL component
while helping to highlight the heterogeneity of cancers. Given the classification of PDAC as
an immunologically “cold” tumor compared to melanoma, it was no surprise to find the level
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of CD3+ TIL infiltration was significantly less. However, it was interesting to note that the
CD3+ TIL component was primarily composed of CD4+ TIL, which has been reported by
others [303, 304]. Given that response to anti-PD1 CBI is correlated with increased CD8+
TIL at baseline, potentially the lack of response to CBI for PDAC could be attributed to the
scarcity of CD8+ TIL [305, 306]. However, the reason for the predominance of CD4+ TIL is
unclear.
One potential mechanism that was elucidated in a mouse model of pancreatic cancer
is the effect of pancreatic stellate cells (PSCs). Activated PSCs in the surrounding stroma
were found to sequester CD8+ TIL peritumorally via secretion of CXCL12 [307]. The same
disparity was observed in PDAC liver metastases and could be due to the same mechanism.
The liver also contains hepatic stellate cells (HSCs) which become activated after livery
injury and can secrete CXCL12 as well [308]. Inhibition of the effects of stellate cells could
be a strategy to improve the effectiveness TIL ACT. One such method could be use of
Plerixafor (Mozobil/AMD3100) to inhibit CXCR4, the receptor for CXCL12, thus
preventing T-cell exclusion in the tumor [309, 310]. Another potential option is
administration of the antifibrotic compound halofuginone, which has been shown to inhibit
PSC activation in addition to making the TME more amenable to immune infiltration by
reducing the tumor stromal content [311, 312].
In addition to cellular mechanisms of CD8+ TIL exclusion, genomic factors could be
important as well. Several groups have conducted genomic analyses and identified different
molecular subtypes of PDAC [313-317]. Furthermore, meta-analysis of these studies resulted
in a putative consensus nomenclature where there are two broad types of PDAC: Squamouslike and Classical-Pancreatic. The Classic-Pancreatic is further subdivided into an Exocrine112

like type, Classic-Progenitor type, and an Immunogenic type [318]. Based on these analyses,
the majority of PDAC cases have a poor immune signature as well as poor prognosis
compared to the immunogenic subtype. The fact that PDAC has a low mutation burden
overall and the majority of PDAC subtypes are weakly immunogenic could explain the lack
of CD8+ TIL component. Moreover, understanding of these molecular subtypes could help
guide selection of those patients that would have a better chance to respond.
Despite the low amount of CD8+ TIL infiltration in PDAC, further phenotyping
shows that these CD8+ T cells found in the fresh tumors bear an activated phenotype,
suggesting anti-tumor activity. The low percentage of CD45RA (10% ± 6%) in combination
with the CD28 (50% ± 20%) and PD-1 expression (45% ± 12%) suggests the population is
mainly effector memory with low to no terminally differentiated cells [319]. In order to dive
deeper into PDAC TIL populations, initial bulk TCR-sequencing of the T cells found in the
blood, tumor, and normal adjacent tissue was performed. TCR-sequencing allows for
analysis of the repertoire of a T cell population. As laid out in section 1.1.3 of the
Introduction, antigen-specific T cell clones will expand at the tumor site if they recognize
their target. TCR-sequencing showed that 5/6 PDAC samples sequenced showed enrichment
of select T cell clones at the tumor in comparison to the blood, suggestive of an immune
response. This data corroborates work by Poschke et al. which also found that the T-cell
repertoire in primary PDAC tumors was enriched versus the blood [303]. Only a subset of the
T-cell clones found in the blood are found in the tumor, and the frequency of a clone in the
blood does not correlate with its frequency in the tumor tissue. Furthermore, T-cell clones
found both in the tumor and in adjacent uninvolved tissue tended to be present at higher
frequency in the tumor tissue than the uninvolved, suggesting local proliferation or active
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enrichment, again indicative of an anti-tumor immune response (Figure 9). However, while
looking particularly at the high-frequency clones shared between the tumor tissue and
adjacent uninvolved tissue, four patients exhibited similarity between the frequencies of
shared TIL clones. This was highlighted by the fact that the top clones appeared to cluster
along the 1:1 frequency line, suggesting that high frequency clones were shared between the
tumor and adjacent uninvolved tissue (Figure 9). A possible explanation of this would be the
contribution of a local immune response as opposed to a systemic one coming from the
blood. This potentially indicates participation of tissue-resident memory T cells.
The idea of the participation of TRM cells in an immune response for PDAC was
particularly intriguing given then wealth of recent data suggesting this population of cells
harbors tumor-reactive T cells or are correlated with improved survival in several tumors
types, including potentially pancreatic cancer [262, 264-267, 320]. Given the complexity and
variability of not only the TRM cell phenotype, but other TIL populations as well, scRNAseq
was employed to assess the phenotypes in an unbiased manner. scRNAseq of 6 PDAC
samples revealed four CD8+ TIL groups (CD8_C1 EOMES, CD8_C2 ZNF683, CD8_C3
GZMB, and CD8_C4 STAT1) and three CD4+ groups (CD4_C1 TCM, CD4_C2 Treg, and
CD4_C3 TEM). While initial flow cytometry analysis indicated that the majority of CD8+ TIL
were effector memory cells, scRNAseq revealed the true heterogeneity of this TEM population
that would have otherwise gone unnoticed. Of particular note is the CD8_C2 ZNF683 group
which appears to be a TRM-like group based on the expression of ZNF683, CD69, and IL-7R
as well as the lack of expression of KLF2, S1PR5, and ZEB2 as reported in the literature
[254, 278]. Interestingly this population does not have high expression of ITGAE (aka
CD103) or checkpoint molecules which have also been repeatedly reported in the literature
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for the TRM population. This could be an indication of a unique phenotype for PDAC TRM
cells or a reflection of T cell anergy given the reported lack of proper T-cell stimulation
which is reported to be necessary for CD103 upregulation [271, 304, 321, 322]. A recent
report found that expression of ZNF683 and IL7R was associated with persistence of infused
TIL clones in the peripheral blood of a treated colorectal cancer patient after TIL therapy
[323]. This correlation suggest that the subset cells found within our CD8_C2 ZNF683 group
may also have increased persistence in PDAC patients treated with TIL therapy. The results
presented in this study coupled with the data in this dissertation point to the potential benefit
of using scRNAseq to track TIL populations from tumor resection to infusion product to
post-treatment in order improve TIL ACT for solid tumors. Finally, another phenotypic
feature of note for the CD8_ZNF683 population is the expression of XCL1, which has been
shown to be important for recruiting cross-presenting DCs as well as stabilizing their
interaction with CD8+ T-cells [324]. It’s possible then that this subpopulation not only
participates in the immune response but also helps propagate it.
The other two major CD8 effector cell populations, CD8_EOMES and CD8_TBET
appear to be on opposite ends of the spectrum based expression of EOMES and TBX21 (aka
TBET). The CD8_TBET appears to be a full-fledged cytotoxic effector population based on
expression of the cytotoxic T cell markers GZMB, NKG7, GNLY and PRF1 while
CD8_EOMES merely appears to be an activated CD8 TIL population based on expression of
MHCII genes, MIP1-b and GZMK. The key to distinguishing their fate lies with the
differential expression of the EOMES and TBX21, which are important transcription factors
for determining the balance between terminal differentiation of effector cells and the selfrenewal of central memory cells. It has been shown that CD8+ T cells expressing EOMES are
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able to compete the memory cell niche and lacking EOMES results in defective long-term
persistence and secondary expansion after rechallenge [325]. On the other side of the coin,
expression of TBX21 is known to drive differentiation of effector T cells instead of centralmemory T cells [326]. This brings up a potential model where the CD8+ effector T cells go
down one differentiation path to the CD8_ZNF683 TRM population or down a different path
which splits into either the cytotoxic, short-lived CD8_TBET population or the
CD8_EOMES population that leads to more effector memory cells or recirculation of central
memory cells. This is potentially supported by integration of the TCR sequencing shown in
the CD8+ TIL Circos plot (Figure 23). Expanded TCR clones, which are clustered at the 5
o’clock and 11 o’clock positions, tended to be found in multiple transcriptomic populations
instead of staying within one cluster. This could indicate that some of the clones are
expanded due to differentiation into the different subtypes, particularly those at the 5 o’clock
position where the CD8_EOMES population is concentrated. Altogether, the scRNAseq data
reveals an interesting insight into the dynamic cycle of CD8+ TIL participating in an immune
response.
On the other side of the T-cell coin from the CD8+ TIL are the CD4+ TIL which have
two interesting populations: CD4_Treg and CD4_TEM. The Treg population had distinct
expression of GITR, OX40, TIGIT, CD39, and 4-1BB, which are known to be expressed by
activated Tregs. However, their most intriguing feature is their expression of IL32 which is
nominally a pro-inflammatory cytokine and does not seem to fit with the immunosuppressive
function of Tregs [327]. In fact, there does not appear to be any literature linking secretion of
IL-32 to Tregs. Instead, there are several reports on the effects of IL-32 in other contexts that
could give clues to role of IL-32 secreting Tregs. It has been shown to induce expression of
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the immunosuppressive factors IDO and ILT4 in macrophages, DCs, and Tregs [327]. As a
result, in the context of HIV, it can actually dampen the antiviral immune response [328].
Additionally, IL-32 can induce IL-6 production which is associated with a more metastatic
phenotype in pancreatic cancer [329]. Since little is known about the role of IL-32 expressing
Tregs, this could serve as a novel Treg population worthy of exploration in pancreatic cancer.
The other CD4 population, CD4_TEM is potentially interesting given its activated
phenotype, particularly its expression of IL-2 and CD40LG, the ligand for CD40. Interim
results for an ongoing clinical trial using chemotherapy plus an agonistic CD40 mAb with or
without anti-PD1 (Nivolumab) has shown very promising results: the ORR among 30
patients has been greater than 50% [330]. Given this data, it’s conceivable that an activated
CD40LG+CD4+ T cell population could engage CD40 on antigen-presenting cells and help
effector T cell activation to ultimately provide some clinical benefit. Apart from activating
CD4 T cells, an agonistic OX40 mAb can abrogate Treg suppression [62]. Therefore, one
possibility could be the addition of an agonistic OX40 mAb to target the CD4_TEM
population while simultaneously depleting the highly activated OX40+ CD4_Treg population.
Given the fact that there are TIL present with a desirable phenotype, a major step
towards developing TIL ACT for tumor types beyond melanoma is showing the feasibility of
TIL culture. One of the main criticisms of TIL ACT has been the length of culture needed to
produce a cellular product ready to treat patients. For metastatic melanoma, in which the
therapy was pioneered, the pre-REP (fragment culture) can take up to 5 weeks using the
“traditional” method of high-dose IL-2 in 24-well tissue-culture plates [331]. This is in
addition to the 2 week REP process needed expand enough TIL to be able to treat a patient,
producing a delay of up to 7 weeks. This prolonged wait time would result in some patients
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no longer being eligible for treatment in the case of a rapid progression. This would be
particularly true in the case of PDAC and OvCa patients, who are often dealing with latestage cancer, and do not have the ability to wait almost 2 months for treatment. Furthermore,
on top of the lengthy wait time is the fact that a successful TIL culture is not guaranteed.
Even for a highly infiltrated tumor type like melanoma, the historical success rate for a
successful TIL culture is 60-70%, which is to say that a sufficient number of TIL was
expanded in the pre-REP phase in order to be able to treat a patient [96, 154, 156, 332]. The
issues of extended culture time and less-than-ideal success rate were recapitulated to even
worse degree in attempting TIL culture for PDAC and OvCa. Using the traditional culture
method, I observed that culture time was consistently 4-5 weeks with success rates of 29%
for PDAC and 41% for OvCa. In addition, this issue of prolonged TIL culture was also
found in early OvCa TIL ACT trials using the traditional TIL culture method, which likely
contributed to the poor results observed along with low cell numbers overall and lack of
lymphodepletion before TIL infusion [296-300]. The question of why some PDAC and OvCa
TIL cultures do not grow with IL-2 is still mostly an open one and several factors could be at
play.
PDAC is generally characterized as an immunologically “cold” tumor that is defined
by a low T-cell infiltrate, an immunosuppressive TME, and a dense desmoplastic component
that excludes immune cells [304]. As it has been observed by me and others, PDAC has a
much lower TIL presence than melanoma [119, 241, 304]. The poor growth observed with
IL-2 only could simply be a function of low T-cell infiltration that is below a threshold
amenable to outgrowth. Another possible explanation is the presence of inhibitory immune
cells that increase the hurdle for T cells to expand, such as the Tregs as shown in the by
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scRNAseq and flow cytometry analysis. The inhibition of TIL in pancreatic cancer has been
frequently attributed to the presence of Tregs [333, 334].

Likewise, other

immunosuppressive factors within the PDAC TME such as IL-10, TGF-b, IDO, myeloidderived suppressor cells (MDSCs) also likely contribute [335].
In the context of OvCa TIL culture, a lack of TIL infiltration would not seem to be an
apparent reason for the failure of 59% of cultures as we observed that the level of infiltration
is quite similar to melanoma. However, we did observe a correlation with a lack of TIL
growth with IL-2 when the percentage of CD3+ TIL in the fresh tumor sample was below 2%
(Figure 33). Due to the variability of immune infiltration in all cancers, not just OvCa, it
stands to reason that some sample will not produce TIL outgrowth simply due to insufficient
TIL numbers. Beyond that, a more complex cellular mechanism could be involved. Recent
work pinpointed an inhibitory population of NK cells that could at least partially explain the
increased difficulty to grow TIL with IL-2 in OvCa [336]. Inhibition of CD3+ TIL expansion
was correlated with concurrent expansion of NK cells (CD3-CD56+) within IL-2 only
cultures. Furthermore, slow-growing TIL cultures were observed to contain more NK cells
than fast-growing cultures. While we observed that NK cells did sometimes expand at the
expense of CD3+ TIL growth, we did not find a correlation between NK cell presence and
lack of TIL growth. Similarly to PDAC, OvCa can harbor the same inhibitory immune
populations like MDSCs and Tregs, as well as immunosuppressive factors like IDO that
could contribute [337].
Beyond the poor success rate and lengthy time of TIL culture with the traditional
method of PDAC and OvCa TIL culture, I also observed that predominantly CD4+ TIL were
produced as opposed to the CD8+ TIL which are correlated with response to TIL ACT. All

119

of these factors greatly reduced the feasibility of TIL ACT for PDAC and OvCa, thus the
implementation of an improved culture method (TIL 3.0) which addressed all these issues.
TIL 3.0 uses 4-1BB and CD3 stimulation to selectively and robustly expand CD8+ TIL with a
95% success rate for both cancer types. The TIL 3.0 method was helpful for OvCa TIL
culture given the fact that 4-1BB stimulation alone caused extensive NK cell proliferation in
some cases, perhaps facilitating their ability to inhibit T-cell growth. The addition of OKT3
to specifically trigger T-cell expansion overcomes the issue of unwanted NK cell growth.
Overall, TIL 3.0 also allowed OvCa cultures to grow that were below the 2% live CD3+ TIL
threshold that prevented many IL-2 only cultures from growing. Importantly, TIL 3.0
allowed for massive CD8+ TIL proliferation in the absence of over differentiation as
indicated by a high percentage of the TIL product expressing CD28 and BTLA, and a low
percentage expressing PD-1.
Apart from being a key co-stimulatory molecule for T cells, CD28 also serves as a
measure of differentiation as it is lost as a T cells becomes more differentiated, particularly at
the terminal differentiation stage. Loss of expression of CD28 on TIL is associated with
weak antigen responsiveness in melanoma as well as a key factor leading to senescence,
while maintained expression is associated with prolonged persistence in ACT patients [161,
338, 339]. A higher percentage of BTLA expressing CD8+ TIL in the infusion product was
correlated with persistence and response in metastatic melanoma TIL treated patients in
previous work here at MDACC [108]. Further work by Haymaker et al. and Ritthipichai et
al. laid out respectively a possible explanation for this by showing that, compared to CD8+
TIL lacking BTLA expression, BTLA+CD8+ TIL are less differentiated (“younger”) and able
to serially kill cancer cells [188, 189]. Finally, we consistently observed that the use of TIL
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3.0 leads to a decreased expression of PD-1 in the expanded TIL (Figures 18 and 34). A low
percentage of PD-1 expressing cells in the TIL product may help lower the risk for T cells
dysfunction due to the PD-1/PD-L1 axis. These results suggest that TIL 3.0 can facilitate TIL
ACT for OvCa and PDAC, and it could likely be applied to other cancer types, including
melanoma.
While producing a phenotypically desirable TIL product is important, they key result
is demonstrating that the TIL culture process produces a large number of tumor-reactive TIL.
CD8+ TIL were tested against tumor targets to demonstrate the anti-tumor potential. For
PDAC, we were able to show reactivity against two autologous tumor targets, demonstrating
the presence of anti-tumor activity in expanded TIL, as also reported by other groups [120,
241, 303]. Only a comparison of reactivity between IL-2 only and IL-2 + a4-1BB grown TIL
was done for PDAC due to the lack of a good tumor target for TIL generated using TIL 3.0.
Both TIL lines, regardless of culture method, showed anti-tumor reactivity. Interestingly,
bulk TCR-sequencing of the TIL products revealed that the top clones detected were not
always the high frequency TIL clones in the tumor and often were low frequency initially.
This is notable given the fact that that the high-frequency clones within the tumor are often
thought to be enriched due to expansion after antigen recognition in melanoma [340].
However, our data indicate that low-frequency TIL also have anti-tumor potential in PDAC.
This was also observed in other GI cancers as well where mutation-reactive TIL were found
at very low frequency [250]. The fact that there are tumor-reactive T cells clones in PDAC
that have not undergone major clonal expansion indicates again the lack of proper
stimulation which is likely related to the dearth of mutations and inhospitable TME. Further
analysis of the T-cell repertoires in IL-2 only or IL-2+a4-1BB culture conditions revealed
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that they produced distinct repertoires. This result stands to reason given the fact that the a41BB mAb selects recently antigen-activated CD8+ TIL expressing 4-1BB whereas IL-2 only
provides a non-specific T-cell growth signal. Consistent with this premise is the observation
that the IL-2+a4-1BB grown TIL appear to harbor a higher percentage of tumor reactive TIL
compared to the IL-2 only grown TIL as shown by the increase in 4-1BB+ CD8+ TIL and
IFN-g secretion. Since adding extra stimulation like a4-1BB increased CD8+ TIL growth, this
indicates the a4-1BB grown TIL product contains a larger number of anti-tumor T cells.
For testing OvCa TIL reactivity, well-established tumor cell lines that were at least
partially HLA-matched to the TIL were used due to the difficulty of establishing autologous
tumor lines. Not all the TIL lines showed reactivity against their HLA-matched tumor target,
which could be an indication that they may recognize a private mutation specific to that
patient as opposed to a shared TAA. Therefore, this does not preclude the fact that the
unreactive TIL products would show anti-tumor reactivity if paired with an autologous
target, which would be the case in the clinical setting as TIL ACT is meant to treat patients
with autologous TIL. Similarly to PDAC, it appears that the improved culture method
resulted in an OvCa TIL product that contained a greater number of tumor reactive TIL as
indicated by the increased number of spots on the IFN-g ELISPOT (Figure 35). While TIL
3.0 grown OvCa TIL showed increased number of tumor reactive cells (max 0.2% of total), it
was less in comparison to melanoma TIL grown using the same method (max 0.8% of total)
[218]. Further single-cell TCR sequencing was done on PDAC TIL grown with TIL 3.0,
showing that the initial frequency of TIL in the tumor was maintained in the cultured
product. For example, this means that high-frequency clones in the tumor were expanded and
remained the dominant clones in the TIL product. Therefore, given the fact that tumor-
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reactive TIL can be found within the high-frequency clones in the tumor, one could assume
that the increased reactivity of the OvCa TIL 3.0 grown cells could be coming from this
compartment.
In addition to TCR sequencing, transcriptomic scRNAseq was performed for TIL 3.0
grown PDAC TIL in order to gain insight into the phenotype of the cultured TIL as well as
from which transcriptomic cluster in the fresh samples were the TIL expanded. Not
surprisingly, the TIL 3.0 cell product is made up predominantly of an activated CD8+ TIL
cluster (CD8_GZMB) and a cycling cluster (CD3_cycling) that’s derived from the CD8
cluster. A small activated CD4 cluster (CD4_OX40) and γδ T cell cluster are also present.
With regards to the CD8+ TIL in the cultured product, it seems the four transcriptomic groups
observed in the fresh TIL have mainly collapsed into one activated CD8 cluster. Given the
fact that CD8+ TIL were expanded from all four groups (including the TRM-like population)
according to TCRseq data, it remains to be seen if any of the features seen in the fresh TIL
are still imprinted on them and would re-emerge in vivo after TIL administration. This is a
particularly interesting question given the previously mentioned report of ZNF683 and IL7R
expression being associated with persistence of TIL in the peripheral blood after TIL therapy
[323]. scRNAseq could also be used to track the infused TIL for these characteristics as well
as look for characteristics associated with persistence and trafficking to the tumor site. The
activated CD4_OX40 cluster retained expression of CD40LG and, given the importance of
CD4+ T cell help to CD8+ T cell function, administration of an OX40 mAb after TIL infusion
could be beneficial.
While the reactivity displayed gives a strong indication of the feasibility of TIL ACT,
it can also be used as a springboard for identifying specific tumor antigens that could be
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targeted with cellular therapy. OvCa TIL reactivity against HLA-matched tumor lines
indicates recognition of shared TAA(s). Moreover, some of the TIL lines are matched on the
same HLA allele. This is particularly interesting in the case of a highly prevalent HLA allele
like HLA-A*02:01, which is shared by 20-50% of the population in the USA, Europe, and
China [341]. Identifying the TCR specific for a shared TAA restricted to this HLA could be
an attractive therapeutic option due to its broad applicability. Endogenous T-cell reactivity
against various TAA has been shown in OvCa such as mesothelin [342], wild-type or
mutated p53 [136, 343, 344], NY-ESO-1 [345], and Her2/neu [346]. The same has been done
for PDAC TAAs such as mesothelin, survivin, NY-ESO-1 [120]. Identifying tumor-specific
mutated antigens (neoantigens) as immunotherapeutic targets is also a big area of interest due
to expression being restricted to only the tumor. There is some indication of the potential of
this therapeutic avenue as showed by isolation of T cells from two OvCa patients that were
specific for the same p53 neoantigen [136]. Likewise, neoantigen reactive TIL were found in
9/10 GI cancer patients, including a pancreatic cancer patient [250]. The ability to target
mutated KRAS, PDACs most prevalent driver mutation, could be possible given results
showing response to mutant KRAS vaccines in PDAC patients as well as detection of mutant
KRAS reactive TIL in colorectal cancer [115, 347]. In fact, a colorectal cancer patient that
was treated with a TIL product containing mutant KRAS-specific TIL showed clinical
efficacy [115]. While the TIL product contained TIL with other antigen-specificities, the
KRAS-mutant specific TIL likely played a major role as indicated by the patient recurring
after having lost expression of the HLA for which the mutant KRAS peptide was restricted.
However, targeting neoantigens beyond a prevalently mutated genes like TP53 for OvCa
(95% of cases) and KRAS for PDAC (94% of cases) could be challenging due to neither
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having a high mutation burden [206]. However, therapies targeting a particular antigen could
be difficult to use given the possibility of target antigen loss. TIL ACT could potentially
avoid these issues by providing antigen specificity against a broad range of TAA.
In conclusion, my work has demonstrated the feasibility of TIL ACT for PDAC and
OvCa by showing that they harbor an activated, anti-tumor CD8+ T-cell infiltrate that can be
robustly and reliably expanded using an improved 3-signal culture method consisting of a
CD3 stimulation, an agonistic 4-1BB mAb, and high-dose IL-2. Additionally, these results
show that TIL ACT for PDAC and OvCa is feasible regardless of primary or metastatic site,
and, in the case of OvCa, in a chemotherapy refractory setting as is often the case.
Furthermore, our understanding of the TIL heterogeneity in PDAC has been increased
through the use of single-cell RNA transcriptomic and T-cell receptor sequencing, revealing
novel TIL populations with potential prognostic implications. It was one of my biggest
dreams that the results of my work could provide some benefit to patients in dire need of
improved therapy options. So, it is with much hope and great expectation that I conclude my
dissertation with the fact that a Phase II clinical trial partly based on this work is ongoing at
MDACC to evaluate the feasibility of the adoptive transfer of autologous tumor-infiltrating
lymphocytes in OvCa and PDAC.
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